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 Alzheimer’s disease (AD) is a multifactorial illness manifesting as gradual 
progressive memory loss, culminating in an end-stage of profound cognitive 
deterioration. While AD pathology is characterized by the presence of beta amyloid (Aβ) 
plaques, clearing Aβ deposits from the brain has not proved sufficient to improve 
cognition. It is thought that the gradual loss of synaptic connections in the telencephalon 
leads to cognitive impairment. Thus, understanding synaptic function and testing 
methods to prevent the loss of synapses are the primary directions of current AD 
research. 
AD pathology in the primary sensory areas of the cortex (the granular or 
koniocortex) is typically found only in the most advanced cases. To gain insight into the 
differences in the synaptic organization of the koniocortex and the eulaminate cortex, we 
compared the distribution and morphology of geniculocortical and pulvinocortical 
terminals in tree shrews. Synaptic terminals were labeled using the stereotaxic injection 
of neuroanatomical tracers or viral vectors, and/or immunohistochemical labeling of the 
type 2 vesicular glutamate transporter (vGLUT2) and gamma aminobutyric acid (GABA). 
Transmitted light, confocal and electron microscopy revealed that geniculocortical 
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terminals in layers IVa and IVb of the striate cortex are significantly larger than 
pulvinocortical terminals in the temporal cortex. Geniculocortical terminals contact 
nonGABAergic dendritic spines (91%) and the GABAergic dendrites of cortical 
interneurons (9%), while pulvinocortical terminals only contact nonGABAergic dendritic 
spines. Geniculocortical terminals often contain small extensions of postsynaptic spines, 
termed “spinules”, while pulvinocortical terminals do not. Analysis of the postsynaptic 
targets of geniculocortical terminals revealed that 14% contained a spine apparatus, an 
organelle related to dendritic spine stability and memory. Our results indicate that the 
organization of thalamocortical synaptic connections is quite different in the konicortex 
and eulaminate cortex. Further comparisons of the synaptic organization of the 
koniocortex and eulaminate cortex may reveal characteristics related to the progression 
of AD pathology.  
The brain areas primarily affected by AD are mirrored by the distribution of 
dendritic spines that contain spine apparati (uniquely identified by the actin-bindng 
protein synaptopodin) and by glutamatergic terminals that contain zinc ions sequestered 
by the type 3 zinc transporter (ZnT3). Because zinc assists in the rapid aggregation of Aβ, 
and zinc levels increase and decrease with brain activity, we examined levels of ZnT3 and 
synaptopodin in the cortex and hippocampus of a transgenic mouse model of AD 
(TgSwDI; this model expresses neuronally derived human amyloid β-precursor protein, 
APP gene, 770 isoform, containing the Swedish K670N/M671L, Dutch E693Q and Iowa 
D694N mutations, under the control of the mouse thymus cell antigen 1, theta, Thy1, 
promoter). Using western blot techniques we measured ZnT3 and synaptopodin levels in 
tissue from mice at 1, 4 and 6 months of age before and after zinc precipitation by 
intraperitoneal injection of sodium selenite. We found that sodium selenite treatment 
produced no significant effect on the levels of synaptopodin. However, we did find that 
ZnT3 levels were higher in TgSwDI mice at 4 months of age in both the cortex and 
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hippocampus when compared to wild type mice (WT) and TgSwDI mice of other ages. 
Also, when compared by ages, synaptopodin levels were higher in 4-month old WT and 
TgSwDI animals in both the cortex and hippocampus. These results suggest that zinc 
may be an important participant in the pathology of AD, but that age-related changes in 
ZnT3 levels should be considered when evaluating treatments involving the 
manipulation of zinc levels. 
Finally, using electron microscopy and immunohistochemical labeling of 
activated microglia with isolectin b4 (Ib4), we investigate the histopathology of the 
cortex and hippocampus in TgSwDI mice. Introduction of Dutch/Iowa mutation caused 
a strong affinity of Aβ deposition near brain vasculature. We found that pathology in the 
brains of TgSwDI mice progresses in the same areal sequence as is seen in human AD 
patients and other AD mouse models. However, the cortex and hippocampus are largely 
devoid of neuritic plaques; the abundance of Aβ accumulation was observed in and 
around blood vessel walls surrounded by microglia cells. Our finding suggest the this 
mouse model of AD is very suitable for investigations of cerebral amyloid angiopathy-
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 Alzheimer’s disease (AD) is characterized by progressive cognitive decline with 
the initial impairment of the ability to form new memories and then gradual involvement 
of all intellectual modalities. This eventually leads to the inability to perform the 
functions of daily life and premature death. AD is the most frequent cause of dementia in 
developed countries. In the United States there are approximately 5.5 million people 
affected, and it is estimated that worldwide there are 24 million people that have AD 
(Mayeux and Stern, 2012). The incidence and prevalence of AD is directly related to the 
age of the population. The incidence of AD rises exponentially after age 65 (Evans et al., 
1989; Brookmeyer et al, 1998). However, about 5 percent of people affected by this 
disease have an early onset form, which is diagnosed when they are in their 40s and 50s 
(Alzheimer’s Disease Association). 
 Pathologically, both sporadic and early-onset AD is characterized by the same 
morphologic elements that include extracellular plaques of beta-amyloid and 
intracellular hyperphosphorylated tangles of the microtubule-associated protein tau 
(Braak and Braak, 1991; Perl, 2010). The latter is also called neurofibrillary tangles and 
they were described by Alois Alzheimer himself in his pioneering work as abnormal 
fibrous inclusions within the perikaryal cytoplasm of pyramidal neurons (Perl, 2010). 
Ultrastructural studies of neurofibrillary tangles reveal the helices of paired 10 nm fibrils 
of tau protein that are hyperphosphorylated in serine/threonine residues by kinases and 
have other attached constituents such as ubiquitin, cholinesterases and beta-amyloid 4 
fibrils to them (Kidd, 1963; Wisniewski et al., 1976; Perry et al., 1987; Mesulam and 
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Moran, 1987; Love et al., 1988; Trojanowski et al., 1991; Avila, 2006; Perl, 2010). Despite 
being a major histopathological factor for diagnosis of AD, neurofibrillary tangles are not 
pathognomonic to this disease only and can be seen in other diseases of the central 
nervous system such as postencephalitic parkinsonism, posttraumatic dementia or 
dementia pugalistica, type C Niemann-Pick disease, and amyotrophic lateral 
sclerosis/parkinsonism dementia complex of Guam and others (Perl, 2010). The range of 
these diseases with their different etiologies, pathogeneses and clinical presentations 
could imply that neurofibrillary tangles are more of a consequence of different 
pathological processes affecting the neuronal tissue than the cause of them. 
Another cardinal histopathological hallmark of AD is the senile plaque, or β-
amyloid plaque, and it is also not totally unique to this disease. It can be seen in Lewy 
body dementia (Armstrong et al., 1997; Jendroska et al., 1997), Parkinson disease 
dementia (Jendroska et al., 1996), and others, even though studies succeeded in 
chemical and structural differentiation of the constituent beta-fibrils that form plaques 
in these etiologically diverse diseases (Wiltfang et al., 2002, Bibl et al., 2006). The core 
of the senile plaque is presented by the accumulation of a 4 kDa protein with a beta-
pleated sheet structure (Beyreuther et al., 1985; Tate et al., 1992). The beta-amyloid 
plaque consists of the central core of beta-amyloid fibrils, arranged in a radial fashion, 
and surrounding it neurites, that include dendrites or axons of dystrophic neurons, 
containing dense bodies, membranous profiles, and packets of paired helical filaments, 
as well as glial cells. Conglomerations of beta-amyloid fibrils, called “diffuse plaques”, 
are also found and they are not surrounded by many dystrophic neurites; these diffuse 
deposits are often times found in the brains of older individuals and do not correlate 
with cognitive impairment (Kidd, 1964; Yamaguchi et al., 1989; Gentleman et al., 1989; 
Morris et al., 1996; Wegiel et al., 2000; Wegiel et al., 2004; Perl, 2010; Holtzman et al., 
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2012). The ultrastructure of senile plaques is described in more detail in Chapter IV of 
this dissertation. 
The distribution of plaques and tangles is a sequential event. The initial 
deposition starts within the phylogenetically oldest part of the cortex – the allocortex, 
which includes the olfactory bulb, entorhinal region, presubicular region, and 
hippocampal formation. As the disease progresses, plaques and tangles are found in the 
mesocortex, which includes the orbitofrontal region, cingluate gyrus and the 
parahippocampal gyrus. In the final stages of the disease, plaques and tangles are 
distributed in the neocortex. In all these areas, the affected neurons are those that form 
connections with other telencephalon areas. Telencephalic neurons with projections to 
the diencephalon, midbrain or hindbrain rarely develop neurofibrillary tangles (Braak et 
al, 2006).  The distribution of amyloid plaques is related to the distribution of zinc in the 
brain, as well as the distribution of dendritic spines that contain a structure known as the 
spine apparatus. As described in more detail in Chapter III, we manipulated zinc levels 
in animal models to explore the role of zinc might play in AD progression   (Arendash et 
al, 2004, Arendash et al., 2007; Costa et al., 2007, Harvey and Svoboda, 2007; Ashby 
and Isaac, 2011; Beique et al., 2012, Mundel et al., 1997; Deller et al., 2003; Vlachos et 
al., 2009, Paoletti et al., 2009). 
 The exact mechanism of β-amyloid formation is not clear, but the sequential 
proteolytic cleavages of ubiquitously expressed transmembrane polypeptide amyloid-
precusor protein (APP) by metalloproteinases β- and γ-secretases is implicated in the 
formation of Aβ40 and Aβ42 isoforms of beta-amyloid that are very capable of 
aggregation into the plaque-like structures. The formation of Aβ is physiological and 
occurs constantly in the normal brain. However, this process can become pathological 
depending on the way the APP is cleaved by secretases (reviewed by Selkoe, 2001; Pluta 
et al., 2013). Most forms of familial (early onset) AD are associated with mutations in 
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genes involved in the processing of APP, but it is still unknown why the scales are shifted 
towards the formation of pathological beta-amyloid in the sporadic cases, and what 
causes its aggregation. The inheritance patterns of AD are not straightforward. The 
mutations in APP, presenilin-1 and presenelin-2 gene (PSEN-1 and PSEN-2) genes are 
mendelian forms and lead to altered structures of APP protein or γ-secretase activity that 
are ultimately responsible for increases in β-amyloid formation. The apolipoprotein E ɛ4  
allele (APOEɛ4) is more complex in terms of inheritance patterns. Being a proven risk 
factor for development of AD, especially with two alleles present, not everyone with this 
allele will develop the disease. The latest genomic studies discovered at least 9 more risk 
loci for the development of AD (reviewed by Broeckhoven et al., 2013).  
The discoveries of genetic mechanisms in AD pathology, have helped scientists to 
develop useful animal models for further investigations of disease. One such model is 
more thoroughly described in Chapters III and IV of this dissertation. However, early-
onset forms represent only the smallest fraction of AD cases, implying that there must be 
other mechanisms and pathways leading to excessive Aβ formation and/or aggregation.  
While, β-amyloid plaques are the most studied histopathological signs of AD, it is 
still unknown whether they the main causative agents of the disease. Since 1992 when 
Hardy and Higgins first formulated their “amyloid cascade hypothesis” it was a 
predominant explanation of etiology and pathogenesis of Alzheimer’s disease.   
According to this hypothesis the accumulation and assembly of Aβ is a primary inciting 
event that leads to the formation of senile plaques, neuronal dystrophy and dementia 
(Hardy and Higgins, 1992; Reitz, 2012).  Recent discoveries related to immunotherapy 
targeted against beta-amyloid in human phase III trials failed to show any improvements 
in the cognitive functioning of patients in the dementia stage of sporadic AD disease 
(Blennow et al., 2012; Sperling et al., 2012; Mullard, 2012; Aisen et al., 2012). Thus, β-
amyloid may not be the sole driver of cognitive impairment per se, as previously thought 
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(Hardy and Allsop, 1991; Hardy and Higgins, 1992; Jellinger, 2009). Rather, it is now 
recognized that a conglomeration of pathological changes throughout the whole brain 
may be responsible for the cognitive deterioration associated with AD. β-amyloid 
deposition is always involved in AD development, but is clearly  linked to other processes 
such as synaptic loss, neuronal degeneration and microglial activation (D’Andrea et al., 
2004; Spires-Jones et al., 2009; Reddy et al.,2010; Mandrekar-Colucci and Landreth 
2010; Spires-Jones and Knafo, 2012).  β-amyloid deposition is now viewed not as the 
cause of AD but rather as just one of the pathogenetic factors of the disease. There is 
strong evidence of patients without cognitive deterioration presenting with β-amyloid 
deposition (Tomlinson et al., 1968; Terry et al., 1991; Bennett et al., 2006; Schneider et 
al., 2007). The poor correlation between the burden of plaques and tangles and cognition 
has been shown in several studies (Tyas et al., 2007; Haroutunian et al., 2008; Iacono et 
al., 2009; Savva et al., 2009; Ewbank and Arnold, 2009). These discoveries stress the 
multifactorial nature of sporadic AD. The failure of immunotherapy to improve cognition 
even after the significant reduction in β-amyloid plaque burden emphasized the 
importance of understanding the events that occur as this neurodegenerative disease 
progresses. Early detection with the possibility of early intervention and prevention of 
this progression has emerged as a primary goal in current studies of AD (Aisen et al., 
2013).  
 This dissertation consists of the three separate chapters presented in a sequence 
that best describes the brain structures and mechanisms that I studied in an attempt to 
understand the basics of Alzheimer’s pathology. In Chapter II I describe a study of the 
ultrastructure of synaptic connections using the visual system as a model. In this Chapter 
I will provide detailed descriptions of the relationships between presynaptic terminals,  
dendritic spines and spine apparati,  the morphological hallmarks of synaptic plasticity 
and memory function (Deller et al., 2003; Dunaevsky and Harms, 2007; Beique et al., 
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2012). With synaptic loss being a major correlate of cognitive deterioration in AD 
(DeKosky and Scheff, 1990; Terry et al., 1991; Spires-Jones et al., 2013) we felt it is 
necessary to study normal terminal connections to better understand their pathology in 
AD.  
Chapter III presents experiments designed to explore possible mechanisms of the 
early stages of AD development. It has been reported  that people exercising higher levels 
of cognitive functions during their lifetime have a decreased chance of developing AD, 
and this is further, supported by studies of animal housed in enriched versus deprived 
environments  (Arendash et al, 2004, Arendash et al., 2007; Costa et al., 2007). Because 
increased zinc levels have been detected in sensory deprived brain regions (Brown and 
Dyck, 2002; Dyck et al., 2003; Land and Shamalla-Hanna, 2002), and zinc is abundant 
in senile plaques (Lovell et al., 1998; Lee et al., 1999; Adlard et al., 2008), we tested the 
hypothesis that zinc levels may be related to the synaptic loss seen in early stages of AD. 
(Spires-Jones and Knafo, 2012). 
Finally, in Chapter IV, we took a closer look at the development and 
ultrastructure of AD pathology using a transgenic mouse model. In particular, the 
involvement of microglia during the different stages of disease was investigated as it is 
still a point of scientific debate whether glial cells involvement in AD is beneficial or 
deleterious (Mandrekar-Colucci and Landreth, 2010; Mrak, 2012; Aguzzi et al., 2013).  
To facilitate understanding of the experiments described in Chapters II-IV, 
several brain structures are described below.   
Hippocampus 
Figure 1.1 displays major anatomic features of hippocampus. The pointed wedge 
of the hippocampus is the dentate gyrus that is characterized by tightly packed layers of 
granule cells. Underlying the dentate gyrus, is the first area of hippocampus proper, CA4, 
that is continuous with zones CA3 to CA1.  These areas are characterized by a layer of 
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pyramidal cells. After CA1 there is a zone called the subiculum, followed by the 
enthorhinal cortex (Amaral and Lavenex, 2006). External inputs come from layer 2 
stellate cells of the enthorhinal cortex; their axons form the perforant path and terminate 
onto granule cells of the dentate gyrus and pyramidal cells of CA3. In addition, layer 3 of 
the enthorhimal cortex sends axons to CA1. Granule cells of dentate gyrus convey passing 
through them neocortical representations by their axons to CA3 and these fibers called 
mossy fibers ( Steward and Scoville, 1976; Claiborne et al., 1986; Acsady et al., 1998). 
From here, pyramidal cells of CA3 send axons to CA1, called Schaffer fibers. In turn, 
pyramidal cells of CA1 send their axons to the subiculum and deeper layers of 
enthorhinal cortex. The subiculum also sends its axons to layer V of the enthorhinal 
cortex, closing the loop (Andersen et al., 1971).  
Mossy Fibers  
The hippocampus is one of the first brain areas affected by amyloid pathology in 
AD (Braak and Braak, 1991). Mossy fibers (MF), which originate from the granule cells of 
the dentate gyrus, are seen to contain very abundant levels of zinc when stained with 
specific protocols (Frederickson et al., 2000; Paoletti et al., 2009). As reviewed by 
Barrionuevo et al, 2000, a single unmyelinated mossy fiber axon originates from each 
granule cell. This axon immediately gives rise to an extensive set of collaterals providing 
input to the polymorphic neurons of the hilus, the area of dentate gyrus beneath the 
granule cell layer that is rich in interneurons (Nicoll and Schmitz, 2005). Mossy fiber 
axons form synapses with excitatory and inhibitory cells of the hilus and area CA3. Even 
though hilar cells are mostly inhibitory interneurons, each of MF axon’s 140-150 
synapses makes about 10 connections with excitatory hilar cells. In CA3 the majority of 
MF synaptic connections are on interneurons and some are on pyramidal cells 
(Claiborne et al., 1986; Acsady et al., 1998). The subset of these interneurons in CA3 
layer (called stratum lucidum) is spiny cells that contain glutamate (Soriano and 
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Frotscher, 1993); these cells are considered local circuit excitatory cells (Barrionuevo et 
al., 2000). This type of interneuron is complemented by another, aspiny type of 
interneuron in CA3, that provides feedforward and feedback inhibition of MF activity 
(Vida and Frotscher, 2000; Lawrence and McBain, 2003). Thus, the large terminals of 
MFs contact CA3 pyramidal cells and hilar mossy cells, the principal cells in dentate 
gyrus hilus. Small terminals and filopodial extensions target GABA-containig neurons in 
the dentate hilus and stratum lucidum of CA3 (Nicoll and Schmitz, 2005). Through these 
complicated and still poorly understood connections, the hippocampus participates in 
the formation of new memories, a process that involves changes in dendritic spines.  
Dendritic spines 
 A dendritic spine is a small protrusion from the dendritic shaft of 
pyramidal neurons in the neocortex and hippocampus, medium spiny neurons of the 
striatum, and other types of neurons. Filopodia are thin, hair-like protrusions that are 
precursors of dendritic spines (Fiala et al., 1998). Dendritic spines are classified in three 
major categories based on morphology: thin, stubby and mushroom. Thin and 
mushroom spines have a neck with a bulbous head whereas stubby spines are devoid of a 
neck. The head of mushroom spines is larger than that of thin spines (Jones and Powell, 
1969; Peters and Kaiserman-Abramoff, 1970; Rochefort and Konnerth, 2012). The same 
spine can change its shape rapidly through activity-dependent or independent 
mechanisms (Harris and Stevens, 1989; Kasai et al., 2010). The majority of excitatory 
synapses occur on the dendritic spines (Bourne and Harris, 2007). Typically, 
glutamateric synaptic connections on spine heads are described as asymmetric synapses; 
this is because the presynaptic density is smaller than the postsynaptic density 
(Rochefort and Konnerth, 2012). It has been suggested that spine morphology 
determines the function of its synapse (Yuste et al., 2000; Kasai et al., 2010) and that the 
induction of long-term potentiation (LTP) of postsynaptic potentials elicited by the 
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presynaptic terminal correlates with spine enlargement (Matsuzaki et al., 2004). In adult 
hippocampus and neocortex only about 25% of spines are mushroom-shaped. They can 
persist for months (Holtmaat et al., 2005). These larger spines can anchor more N-
methyl D-aspartate (NMDA) receptors and α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) glutamate receptors to make synapses functionally stronger 
(Matsuzaki et al., 2001; Ganeshina et al., 2004; Ashby et al., 2006; Bourne and Harris, 
2007). These features suggest that mushroom spines are more stable ‘memory spines’ 
(Kasai et al., 2003; Bourne and Harris, 2007). It has been shown that the induction of 
LTP increases spine head size (Lang et al., 2004; Matsuzaki et al., 2004; Kopec et al., 
2006), whereas long term depression (LTD) decrease spine size (Zhou et al., 2004) or 
causes spine retraction (Nagerle et al., 2004).  
The mushroom spines are associated with the spine apparatus organelle, which is 
composed of stacked smooth endoplasmic reticulum (Vlachos, 2012). A marker for the 
location of spine apparati, and an essential component of spine apparati is synaptopodin, 
an actin-binding protein (Mundel et al., 1997; Deller et al., 2003). Synaptopodin-
deficient mice do not form spine apparati and show deficits in LTP and spatial learning 
(Bas Orth et al., 2007; Deller et al., 2007; Jedlicka et al., 2008; Vlachos, 2012). Since 
there is evidence of impaired spine stability in Alzheimer’s disease (Spires-Jones et al., 
2007; Spires-Jones and Knafo, 2012; Knafo et al., 2012) we considered it worthwhile to 
investigate the above mentioned structures more closely in this dissertation. 
Visual system 
 The primary visual pathways of the brain transmit information from the retina, to 
the dorsal lateral geniculate nucleus (dLGN) to the primary visual cortex (V1), or striate 
cortex From V1, visual signals are transmited  in two general streams,  dorsal and 
ventral. The dorsal stream conveys information to middle temporal areas (also known as 
MT or V5) and the inferior parietal cortex. This stream is referred as “where” or “how” 
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pathway, because it represents visual motion, object location and movement control. The 
ventral stream conveys information through area V4 to the inferior temporal lobe. This 
pathway is called the “what pathway” and is associated with form recognition and object 
representation and the storage of long-term memory (Ungerleider and Mishkin, 1982; 
Goodale and Milner, 1992; Ungerleider, 1995). Pathways through V1 are referred to as 
the primary pathways because lesions of V1 generally lead to an absence of visual 
perception. However, secondary visual pathways from the retina to the superior 
colliculus to thalamic nuclei such as the pulvinar nucleus also exist. These pathways are 
thought to be responsible for the responses to visual stimuli complete that can exist in 
the absence of perception (Stoerig and Cowey, 1997; Collins et al., 2003; Collins et al., 
2005; Danckert and Rossetti, 2005). The interconnections of the superior colliculus, the 
pulvinar nucleus and the  cortical and subcortical targets of the pulvinar nucleus are 
thought to participate in directing visual attention and visually guided movement 
(Chomsung et al., 2010).  
 There are two general types of thalamic neurons: relay cells and interneurons. 
The relay neurons send axons to the cortex and/or subcortical targets such as the 
amygdala and corpus striatum (Day-Brown et al., 2010). Relay cells are glutamatergic. 
The interneurons project locally within the thalamus and contain gamma aminobutyric 
acid (GABA) (Paletsini et al., 1993). Chapter II of this dissertation deals with the 
anatomy of the synaptic connections made by the dLGN in V1 and by the  pulvinar 
nucleus in the temporal cortex. 
 The neurons of the neocortex can be divided into two broad categories: spiny 
excitatory cells (approximately 80% of the total neuronal population) and smooth 
inhibitory cells (approximately 20%) (Brown and Hestrin, 2009). There are 2 major 
classes of excitatory neurons in the cerebral cortex, including V1. The pyramidal cells are 
the principle source of efferent cortical axons (Lund et al., 1975; Katz 1987; Buhl and 
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Singer, 1989; Hubener et al., 1990; Einstein and Fitzpatrick, 1991). Their interlaminar 
and collateral horizontal connections provide synaptic contact with other cortical 
neurons (Gilbert and Wiesel, 1979, 1983; Martin and Whitteridge, 1984; Carder and 
Hendry, 1994) in layers II, III, V and IV, creating the basic circuit across different areas 
of cortex (Feldman, 1984; Martin and Whitteridge, 1984; Carder and Hendry, 1994). 
These pyramidal cells are found to be gutamatergic (Carder and Hendry, 1994) and 
zincergic as well (Brown and Dyck 2005; Miyashita et al., 2007). Pyramidal cells are 
found in all cortical areas. Spiny stellate cells have only been described within the 
koniocortex (or granular cortex) i.e. regions of the cortex that contain densely packed 
cells in layer IV.  Within these cortical areas, which includes V1, the spiny stellate cells 
are restricted to layer IV where they receive thalamocortical innervation. From there, 
spiny stellate cells can send some axons into other areas of the cortex, but the majority 
form exclusively intracortical connections with neurons in the superficial layers (Lund, 
1973; Carder and Hendry, 1994). Interneurons can be differentiated by anatomical, 
physiological and molecular criteria (for review, Petilla Interneuron Nomenclature 
Group, 2008). They form complex networks in neocortex by selective chemical and 
electrical synapses on pyramidal cells and other interneurons playing a major role in 
shaping neocortical activity (Brown and Hestrin, 2009). This inhibition may improve 
orientation sensitivity, spatial frequency selectivity and specifying the spatial position of 
an object's border (Hirsch et al., 2003).  
In summary, this work developed as the attempt to reveal certain pathogenetic 
principles in the progression of Alzheimer’s disease, with a parallel deeper look into the 









Figure 1.1  A. The hippocampus anatomy. (A) Pointed wedge represents dentate gyrus, 
granule cells of which form mossy fibers. Mossy fibers relay information to hilus and 
CA3 area of hippocampus, form where through the series of axonal connections 
information is relayed to CA2, CA1 and subiculum, scale = 100 µm. (B) Schematic of 
hippocampal anatomy and connectivity depicted by Cajal (1911). Arrows demonstrate 
the fiber connectivity of the trisynaptic pathway in the hippocampus. In this circuit, 
entorhinal cortex (ent) neurons innervate dentate granule neuron dendrites via the 
perforant pathway. Granule cell axons, called mossy fibers, then project to CA3 
pyramidal neurons. A diffuse projection of CA3 axons forms the Schaffer collateral 
system innervating the CA1 strata radiatum and oriens. Finally, axons from CA1 and 
CA3 project via the alveus to the fimbria. The orientation and localization of these 
pathways define anatomical layers within the hippocampus [1 = subiculum, 
2 = perforant pathway axons, 3 = molecular layer, 4 = granule cell layer, 5 = hilum, 
6 = mossy fiber axons, 7 = CA3 pyramidal neurons, 8 = Schaffer collateral axons, 
9 = stratum lacunosum–moleculare, 10 = stratum radiatum, 11 = CA1 pyramidal 
neurons, 12 = stratum oriens, 13 = dorsal hippocampal commissure, 14 = alveus, 
15 = fimbria; DG – dentate gyrus] Figure and legend adopted and modified from 














ULTRASTRUCTURAL COMPARISON OF GENICULOCORTICAL AND 
PULVINOCORTICAL PROJECTIONS IN THE TREE SHREW 
Introduction 
The striate cortex is referred to as koniocortex or granular cortex because layer IV 
contains a population of small densely packed neurons, many of which can be identified 
as spiny stellate cells (Douglas et al 2004). Studies in primates have shown that 
geniculocortical terminals primarily contact spiny stellate cells, and additionally contact 
non-spiny interneurons (Hendrickson et al., 1981; Peters and Payne, 1993; da Costa and 
Martin, 2011). The extrastriate visual cortex is referred to as eulaminate or homotypical 
cortex because the cell size and packing density within layer IV is not distinctly different 
from that found in other layers. This suggests that spiny stellate cells are not common in 
this region of the cortex, and further suggests that the organization of thalamocortical 
synapses is likely to be significantly different in granular versus homotypical cortical 
areas. Our previous study of the projections from the pulvinar nucleus to the temporal 
cortex in the tree shrew (Tupaia) revealed that pulvinocortical terminals innervate layers 
I-IV, where they all contact dendritic spines (Chomsung et al., 2010). The goal of the 
current study was to examine the ultrastructure of geniculocortical terminals in the tree 
shrew so that we could directly compare the characteristics of thalamocortical terminals 
in the striate and extrastriate cortex of the same species.   
Although now classified in the order Scadentia, tree shrews are still considered to 
represent a prototype of early prosimian primates. This is because the tree shrew visual 
system exhibits many of the characteristics of the primate visual system, including a 6 
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layered dorsal lateral geniculate nucleus (dLGN) (Kaas and Preuss 1993; Kaas 2002).   
Layers 1 and 4 of the tree shrew dLGN receive input from the ipsilateral retina, while 
layers 2 and 5 receive input from the contralateral retina. Layers 3 and 6 receive input 
from the superior colliculus (Diamond et al., 1980, 1981, 1982). Layers 1, 2, 4, 5 and 6 
project to layer IV of the striate cortex, while layers 3 and 6 project to layers I-III. Layer 
IV is divided into two sublayers IVa and IVb. IVa sublayer receives inputs from dLGN 
layers 1, 2 whereas IVb receives projections from layers 4 and 5 (Conley et al., 1984). In 
this way, both subtiers of layer IV receive information from the ipsi- and contralateral 
retina (Figure 2.1).  
Materials and Methods 
 A total of 5 adult tree shrews (Tupaia belangeri) were used for the 
experiment.  One adult tree shrew was used to label geniculocortical terminals in the 
area IVb of primary visual cortex (V1) by anterograde transport. The injection of adeno-
associated virus (AAV) coupled to fluorescent protein TdTomato in the layer 1 of 
ipsilateral dorsal geniculate nuceus (dLGN) was used (TS 12-01V). Selected sections were 
stained with antibody against TdTomato (Living Colors® DsRed polyclonal antibody 
made in rabbit, 1:1000, Clontech) or the type 2 vesicular glutamate transporter 
(vGLUT2, made in guinea pig, 1:10000, Chemicon Temecula, CA) and embedded for 
electron microscopy (EM). The data about labeled thalamocortical terminals by 
anterograde transport with biotinylated dextran amine (BDA) injection (3000 MW; 
Molecular Probes, Eugene, OR) in the pulvinar nucleus was collected by previous 
investigators and used for this experiment as described before by Chomsung et al., 2010. 
In short, 4 tree shrews received an injection of BDA in the pulvinar nucleus. All the 
methods used were approved by the University of Louisville Animal Care and Use 




Injection of virus and BDA   
Tree shrews that received AAV carrying a vector for channelrhodopsin 1 and 2 
fused to tdTomato (Vector Biolabs, serotype 2/1, titer = 2.0×1012 VG/ml) and BDA 
injection were anesthetized with intramuscular injection of ketamine (100mg/kg) and 
xylazine (6.7mg/kg) mixture. As needed, additional supplements of that mixture were 
administered to assure deep anesthesia until the injection procedure was complete. The 
tree shrews were placed into a stereotaxic apparatus and prepared for sterile surgery. 
Using scalpel, the vertical cut of the skin overlying the skull was done along the middle 
line and the skull exposed for perforation. A small area of the skull overlying dLGN (TS 
12-01V) and pulvinar nucleus (4-05-5, 5-06-6AB, 8-06-1D, 10-04-1AB) was removed and 
the dura reflected. The pressure injection was made using 34 gauge needle attached to a 
nanofil syringe; an utlramicropump UMP-4 was used to eject 100 nl at a rate of 30 
nl/min.  For BDA, a glass pipette with tip diameter of 3 µm filled with BDA in 5% saline 
was lowered vertically and BDA injected ionophoretically using positive 2 µA current for 
30 minutes.   
Immunohistochemistry 
Several antibodies were used in the experiment. Some sections from tree shrew 
injected with virus was stained with anti-DsRed antibodies.  After the tree shrew 
survived for 7 days, it was given a lethal dose of ketamine (600 mg/kg) and xylazine (130 
mg/kg) and was perfused with Tyrode solution, followed by a fixative of 2% 
paraformaldehyde and 2% glutaraldehyde in 0.1M phosphate buffer, pH 7.4 (PB). After 
the brain was removed from the skull, it was sectioned using a vibratome with a 
thickness of 50 µm and placed in PB. To reveal virus labeled terminals, sections were 
incubated with antibody against TdTomato (Living Colors® DsRed polyclonal antibody 
made in rabbit, 1:1000, Clontech).  To reveal BDA, section were incubated in a 1:100 
dilution of avidin and biotinylated horseradish peroxidase (ABC; Vector Laboratories, 
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Burlingame, CA) in phosphate-buffered saline (0.01 M PB with 0.9% NaCL, pH 7.4; PBS) 
with 1 % normal goat serum (NGS) overnight at 4°C. After that the sections were rinsed 
in PB and reacted with nickel-intensified 3,3’-diaminobenzidine (DAB) for 5 minutes and 
subsequently washed in PB 3 times. After the third wash, sections were mounted on 
slides for light microscope examination or were prepared for electron microscopy (as 
described by Chomsung et al., 2010).  
Other sections from this animal were stained with antibody against the vGLUT2 
(1:10000) made in guinea pig (Chemicon Temecula, CA) to reveal geniculocortical 
terminals. For that, after preincubating the sections in 10% NGS and 0.1% Triton X-100 
in PBS for 30 minutes, they were placed in solution containing anti-vGLUT2 antibodies 
and incubated overnight at 4ºC. After rinsing the sections in PB they were placed in a 
1:100 dilution of biotinylated goat anti-guinea pig IgG (Vector Laboratories, Burlingame, 
CA) in 1% NGS/PBS for 1 hour at room temperature. The sections were rinsed in PB 
three times and subsequently reacted with nickel-enhanced DAB for 5 minutes. After 
thorough rinse in PB, the sections were prepared for electron microscopy.  
After sections were prepared, cut and mounted for electron microscopy 
(described below), they were stained for GABA by using previously reported techniques 
(Patel and Bickford, 1997). For this, the GABA antibody made in rabbit (Sigma Chemical 
Company, Saint Louis, MO) in concentration of 1:2000 were tagged with a goat-anti-
rabbit antibody conjugated to 15 nm gold particles (Amersham, Arlington Heights, IL). 
For double-labeling of terminals tissue injected with virus was stained for anti-
vGLUT2 antibodies (1:10000) with secondary anti-guinea pig AlexoFluor-488-
conjugated antibodies (1:2000) (Invitrogen). After washing the sections in PB 3 times, 
they were mounted on slides using ProLong® Gold antifade agent (Invitrogen). After 





To prepare tissue for electron microscopy, selected sections that contained 
terminals labeled with DAB to reveal the location of BDA, TdTomato or vGLUT2 were 
postfixed in 2% osmium tetroxide, dehydrated in ethyl alcohol series and preincubated 
in Durcupan resin overnight in a vacuum chamber. The next day, these sections were flat 
embedded between two sheets of Aclar plastic (Ladd Reasearch, Williston, VT). Using a 
light microscope, the sections were examined to select  areas of interest. Selected areas 
were mounted on reisn blocks and ultrathin sections (70-80 nm) were cut using a 
diamond knife. Ultrathin sections were collected on Formvar-coated nickel slot grids. 
Selected ultrathin sections were stained for GABA as described above. After air drying 
the sections were stained with a 10% solution of uranyl acetate in methanol for 30 
minutes and examined with an electron microscope. 
Ultrastructural data analysis 
Prepared ultrathin sections were examined using a Phillips CM10 electron 
microscope equipped with a digital camera (SIA-12C). Images of labeled terminals that 
were involved in synaptic contacts were captured at a magnification of 18000X. Using 
Maxim DL © 5 software the area of the pre- and postsynaptic profiles was measured. 
The presence or absence of spine apparati, and spinules were noted and the gold particle 
density within pre- and postsynaptic profiles was calculated. The ultrastructural features 
of adjacent terminals were also noted. The postsynaptic profiles were considered to be 
GABAergic if the gold particle density was at least 2 times the density found in the 
presynaptic thalamocortical terminals.  For statistical analysis of size differences an 







Distribution and morphology of geniculocortical and pulvinocortical 
terminals  
Figure 2.2 illustrates the location of virus injection in the dLGN. The BDA 
injection was limited to the most lateral layers of the dLGN - layers 5 and 6 (figure 2.3). 
After the virus injection, TdTomato expression was primarily limited to the most medial 
layer of the dLGN -layer 1. Confirming previous reports (Fitzpatrick, 1996) the BDA 
injection labeled geniculocortical terminals in layer IVb and III of V1 while the virus 
injection labeled terminals in layer IVa of V1. The labeled geniculocortical axons 
exhibited beaded boutons along their length with single axons extending horizontally 
and parallel to the cortical surface in layer IVa or IVb (figure 2.3, 2.4).  In contrast, 
pulvinocortical axons in the temporal cortex (described in Chomsung et al. 2010), extend 
vertically from layer IV to layer I, with beaded axons oriented perpendicular to the 
cortical surface (Figure 2.4).  
 
Geniculocortical terminal vGLUT2 content 
To investigate whether geniculocortical terminals contain vGLUT2, we incubated 
sections that contained TdTomato-labeled geniculocortical terminals with the anti-
vGLUT2 antibody and tagged this antibody with Alexafluor 488. Examination of this 
tissue with a confocal microscope revealed that many TdTomato-labeled geniculocortical 
terminals were labeled with the vGLUT2 antibody (white areas in Figure 2.5). To 
quantify the colocalization of TdTomato and vGLUT2, we used ImageJ software to 
calculate the percent TdTomato-labeled axons (purple + white) that contained vGLUT2 
(white). We only analyzed areas that included both TdTomato and vGLUT2 labeling to 
account for limitation in antibody penetration. Three images of 0.5 µm scan thickness 
were analyzed. Using this method, we calculated that 19.63 ± 1.6% of the TdTomato-
20 
 
labeled axons contain vGLUT2. This is comparable to previous studies of 
geniculocortical terminals using these methods (Nahmani and Erisir, 2005). The 
relatively low percentage of double-labeling reflects the fact that vGLUT2 is only 
contained within synaptic terminals and is absent from portions of axons that do not 
contain vesicles (Nahmani and Erisir; 2005; Chomsung et al., 2008).   
Synaptic targets of geniculocortical terminals in the sublayer IVa of visual 
cortex  
 We examined the synaptic targets of 100 geniculocortical terminals in layer IVa 
labeled by adenovirus injection into the layer 1 of dLGN and 106 geniculocortical 
terminals labeled with the anti-vGLUT2 antibody in layer IVa of the same tree shrew. 
The size of the geniculocortical terminals labeled by the anti-vGLUT2 antibody (mean 
area 1.23 ± 0.34 µm2) was found to be significantly (p < .001) larger than the size of 
terminals labeled from adenovirus injections in layer 1 of the dLGN (mean area 0.93 ± 
0.54 µm2).   
The geniculocortical terminals labeled by either method formed asymmetric 
contacts with spines and small dendrites of similar sizes (mean area of profiles 
postsynaptic to TdTomato-labeled terminals was 0.36 ± 0.2 µm2, mean area of profiles 
postsynaptic to vGLUT2-labeled terminals was 0.34 ± 0.2 µm2, p=.2). The majority of 
these synaptic contacts were classified as simple, i.e. the terminal and postsynaptic 
profile were connected by a synaptic cleft with one continuous postsynaptic density (72% 
of the TdTomato-labeled terminals made simple contacts and 60% of the vGLUT2-
labeled terminals made simple contacts). The remaining synapses were classified as 
perforated (two separate postsynaptic densities were identified in the postsynaptic 
profile; 25% of synapses made by TdTomato-labeled terminals, 33% of synapses made by 
vGLUT2-labeled terminals) or multiple (more than two separate postsynaptic densities 
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identified; 3% of synapses made by TdTomato-labeled terminals, 7% of synapses made 
by vGLUT2-labeled terminals).  
The examined sections were stained for GABA as described in the methods 
section to evaluate whether geniculocortical terminals contact GABAergic cells. The 
density of gold particles overlying pre- and postsynaptic profiles was calculated to 
classify profiles as GABAergic or nonGABAergic.  With the presumption that 
geniculocortical terminals are non-GABAergic (Chomsung et al., 2009), the gold particle 
density overlying presynaptic profiles was considered to represent background staining. 
Postsynaptic profiles were considered to be GABA-positive if they displayed a gold 
particle density at least two times greater than that of the adjacent presynaptic profile. 
According to this criterion, the majority of profiles postsynaptic to labeled 
geniculocoritecal terminals were non-GABAergic (91% of profiles postsynaptic to 
TdTomato labeled terminals and 92.5% of profiles postsynaptic to vGLUT2-labeled 
terminals). Representative electron micrographs are illustrated in Figure 2.6. 
Comparison of the synaptic targets of geniculocortical terminals in layer IVa 
and IVb  
We compared the ultrastructure of vGLUT2-labeled terminals in layer IVa and 
IVb in tissue from the same animal. We compared 106 synapses in sublayer IVa and 105 
synapses in sublayer IVb. We found that vGLUT2-labeled terminals in sublayer IVa were 
significantly larger than vGLUT2-labeled terminals in IVb (mean area 1.23 ± 0.34 µm2 in 
IVa, mean area 1.0 ± 0.53 µm2 in IVb, p=.002). The terminals in both sublayers formed 
asymmetric synapses with spines and small dendrites of comparable size (0.34 ± 0.2 µm2 
in IVa and 0.32 ± 0.15 µm2 in IVb, p=.03). The majority of synaptic contacts were simple 
(60% simple, 33% perforated and 7% multiple in IVa and 71% simple, 26% perforated 
and 3% multiple in IVb). Lastly, the majority of postsynaptic dendrites contacted by the 
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labeled terminals were non-GABAergic in both sublayers (92.5% in IVa and 90.5% in 
IVb). The results are summarized by the graphs in Figs 2.7 and 2.8.   
Ultrastructural characteristics of the postsynaptic targets of 
geniculocortical terminals 
Because the presence of a spine apparatus is correlated with spine volume as well 
as the amplitude of postsynaptic potentials generated by the terminals presynaptic to 
them (Vlachos et al., 2009; Segal, 2010), we quantified the size of labeled 
geniculocortical terminals and their postsynaptic targets that contained spine apparati 
and compared them to the size of labeled geniculocortical terminals and their 
postsynaptic profiles without spine apparati. We found that postsynaptic targets with 
clearly identifiable spine apparati comprised only 14% of all targets contacted by labeled 
geniculocortical terminals (total n=311). Spine apparati were only found in non-
GABAergic profiles. We found only slight differences in the size of nonGABAergic 
profiles contacted by labeled geniculocortical terminals that did or did not contain spine 
apparati (mean area of postsynaptic targets with spine aparati 0.37 ± 0.17 µm2, n=43; 
mean area of postsynaptic targets without spine apparati 0.33 ± 0.17 µm2, n=241; 
p=.053). The size of the labeled terminals contacting profiles with spine apparati (1.078 
± 0.59 µm2) was almost identical to the size of terminals contacting profiles lacking spine 
apparati (1.073 ± 0.59 µm2, p=.48).  
We also examined the types of synapses made by geniculocortical terminals on 
profiles with and without a spine apparatus and found that contacts on spines that 
contained a spine apparatus were more complex (54.5% formed perforated synapses and 
11.5% formed multiple contacts) than contacts on spines that did not contain a spine 
apparatus. When calculated relative to each type of geniculocortical synaptic contact, 
only 7% of all simple contacts were formed with spines that contained a spine apparatus, 
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whereas approximately one third of all perforated (31%) or multiple (36%) synapses were 
formed with spines that contained a spine apparatus (figure 2.9).  
Erisir and Dreusicke, 2005, noted that geniculocortical terminals in the ferret 
contain small protrusions “spinules” that are extending from spines and embedded 
inside the terminal bouton (figure 2.6). We found that 58% of geniculocortical terminals 
labeled by AAV contained spinules, whereas nearly none of pulvinocortical terminals and 
geniculocortical terminals labeled by vGLUT2 contained them. 
Comparison of the synaptic targets of geniculocortical terminals and 
pulvinocortical terminals 
We compared the features of the 311 geniculocortical synapses examined in this 
study to 444 pulvinocortical synapses examined in the previous study from our 
laboratory (Chomsung et al, 2010). The size of geniculocortical terminals (mean area 
1.06 ± 0.58 µm2) was significantly (p < .001) larger than the size of pulvinocortical 
terminals (0.51 ± 0.28 µm2). The postsynaptic targets contacted by geniculocortical 
terminals were also significantly (p < .001) larger (mean area 0.34 ± 0.19 µm2) than 
those contacted by pulvinocortical terminals (0.28 ± 0.11 µm2). Pulvinocortical synapses 
were as a group more complex (51% simple, 35% perforated, 14% multiple) than 
geniculocortical terminals (71% simple, 28% perforated and 4% multiple). Finally, 
pulvinocortical terminals did not contact any GABAergic profiles whereas 9% of 
geniculocortical terminals contacted GABAergic dendrites. These results are summarized 
in figure 2.10. 
 
Discussion 
Comparison with previous studies of geniculocortical terminals 
The distribution of geniculocortical terminals labeled by our tracer and 
adenovirus injections confirm previous tree shrew studies (reviewed by Fitzpatrick 
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1996). We found that an injection in layer 1 of the dLGN labeled terminals in sublayer 
IVa of V1 and an injection sin layer 5 and 6 of the dLGN labeled terminals in layer IVb 
and III of V1. The labeled geniculocortical axons formed arbors that are oriented parallel 
to the cortical surface, similar to the orientation of the dendrites of spiny stellate cells 
(Muly and Fitzpatrick, 1992).  
The ultrastructure of the labeled geniculocortical terminals, as well as terminals 
labeled with an antibody against vGLUT2, was similar to previous description of 
geniculocortical terminals in the mouse, ferret, cat and primate (Garey and Powell, 1971; 
Freund et al., 1989; Dehay et al., 1991; Erisir and Dreusick, 2005; Nahmani and Erisir, 
2005; Coleman et al., 2010; daCosta and Martin, 2011). Most previous studies have 
described geniculocortical terminals as large terminals that primarily contact dendritic 
spines. Our results also are comparable to previous studies that have examined the 
percentage of contacts on GABAergic and nonGABAergic dendrites. Erisir and Dreusicke 
(2005) found that 9% of geniculocortical terminals in the adult ferret contact GABAergic 
dendrites, which is precisely the percentage of contacts on GABAergic dendrites revealed 
in our study. Freund et al (1989) found that 4.5-9.5% of geniculocortical terminals in the 
adult macaque monkey contact GABAergic dendrites. 
We also confirmed geniculocortical terminals in the tree shrew contain vGLUT2, 
as has been found in the ferret (Nahmani and Erisir, 2005) and mouse (Coleman et al., 
2010).  Not all geniculocortical axons were double-labeled with the vGLUT2 antibody, 
but this can be attributed to limitations in antibody penetration as well as the fact that 
vGLUT2 is limited to regions of the axons that contain synaptic vesicles.  We did find 
that terminals labeled by the vGLUT2 antibody in layer IVa were larger as a population 
compared to the terminals labeled by the adenovirus injection in dLGN layer 1. The fact 
that the same animal was used for quantifying all terminal types eliminates the 
possibility that fixation differences can account for any size differences. One explanation 
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could be that geniculocortical terminals that originate from dLGN layer 2 are larger than 
those that originate from layer 1. Alternatively, vGLUT2 may be more densely distributed 
in larger terminals, which contain greater numbers of vesicles, and immunocytochemical 
detection may be skewed toward larger terminals.  However, vGLUT2-labeled terminals 
in layer IVb were smaller than the vGLUT2-labeled terminals in layer IVa. This could 
potentially be related to the size of cells in the various geniculate lamina. Brauer et al 
(1983) found that cells in layer 1 and 2 of the tree shrew dLGN are larger than cells in 
layers 4 and 5, and therefore may give rise to larger terminals. 
Spines and spinules 
Spine apparati are composed of stacked smooth endoplasmic reticulum and 
found only in most mature dendritic spines of the hippocampus (Segal, 2010; Vlachos, 
2012). This organelle together with its uniquely associated protein synaptopodin, is 
thought to participate in the long-term potentiation of synapses and spatial learning 
(Deller et. al., 2003, 2007; Jedlicka et al., 2008, 2009).  It has been shown that in 
cultures of the mouse hippocampus the heads of the spines containing spine apparati 
were larger than spines that did not contain a spine apparatus (Vlachos et al., 2009). To 
investigate whether this also holds true for spines postsynaptic to geniculocortical 
terminals, we measured area of the postsynaptic spines that did or did not contain a 
spine apparatus. Only 14% of all geniculocortical targets contained a spine apparatus. All 
were nonGABAergic, as previously described by Freund et al. (1989).  The size of 
postsynaptic spines that contain a spine apparatus was slightly larger than the size of 
spines that did not contain spine apparati, but this difference was not found to be 
significant.  Likewise, there was no significant difference in the size of the terminals that 
contacts spines with or without a spine apparatus. However, we did find that synapses 
associated with spine apparati were more complex (perforated or multiple synapses) 
than synapses on spines that did not contain a spine apparatus.  Thus, although future 
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studies are necessary to determine how spine apparati are related to synaptic function, 
the presence of spine apparati in the visual cortex may be associated with differences in 
the distribution of postsynaptic receptors and the resulting strength of synaptic 
connections, as has been found in the hippocampus.  
We also found the presence of spinules in tree shrew geniculocortical terminals, 
as was reported by Erisir and Dreusick (2005) in the ferret and Freund et al., 1989 in the 
adult monkey’s V1. We found that 58% of all geniculocortical terminals had spinules in 
them. Although, the origin and formation process of spinules is not well understood, it 
has been shown that their formation is induced by heightened synaptic activity with their 
possible role in adjusting synaptic size in face of intense activity (Tao-Cheng et al., 
2009).  
Comparison of geniculocortical terminals in the on and off 
sublamina 
To investigate whether there are any differences in geniculocortical terminals 
related to the organization of the on and off sublamina of the visual cortex, we compared 
vGLUT2-labeled terminals in layer IVa and IVb. We found that geniculocortical 
terminals and their postsynaptic targets were significantly larger in layer IVa, when 
compared to layer IVb. As discussed above, this could be related to finding that cells in 
the dLGN layers 1 and 2 are larger than cells in dLGN layers 4 and 5 (Brauer et al., 1983).  
We also found that more geniculocortical synapses in layer IVa were complex (perforated 
or multiple, 40%) when compared to geniculocortical synapses in layer IVb (29%).  
Finally, we found similar numbers of synapses on GABAergic profiles in layer IVa (7.5%) 
and IVb (9.5%). Thus, while there were subtle differences in the geniculocortical 
synapses within layer IVa and IVb, there were no obvious structural differences that 
would differentially influence the receptive field properties in these sublamina. Freund et 
al., (1989) came to a similar conclusion after comparing the ultrastructure of 
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geniculocortical axons originating from the magno and parvocellular layers of the 
primate dLGN.   
Comparison of geniculocortical and pulvinocortical terminals and 
their synaptic targets 
We compared the data collected in the present study to that collected in a 
previous study of pulvinocortical connections (Chomsung et al., 2010). We found that 
geniculocortical terminals and their postsynaptic profiles are significantly larger when 
compared to pulvinocortical terminals and their postsynaptic profiles (figure 2.9). We 
also found that geniculocortical terminals contain abundant spinules (as in Freund et al 
1989; Erisir and Dreuskicke, 2005), but pulvinocortical terminals contain none. This 
suggests that spinules may be a structure that is unique to spiny stellate cells. However, a 
similar morphology has been described for corticocortical terminals in area MT (V5) that 
originate from V1 (Anderson et al., 1998), even though spiny stellate cells have not been 
described in this region of the cortex. It has been suggested that one function of the 
elaborate morphology of terminals with embedded spinules may be to secure efficient 
and reliable transmission (Anderson et al., 1998). In this regard, it is of interest that the 
response properties in area MT have been shown to decrease dramatically after lesions of 
V1, whereas pulvinar lesions have a smaller effect (Leiby et al., 1982; Bender and Butter, 
1987). In the hippocampus, spinules have also been described in the dentate gyrus 
(Tarrant and Routtenberg, 1977) and CA1 region (Spacek and Harris, 1998) and the 
number of spinules increases in response to synaptic activity (Applegate and Landfield, 
1988; Schuster et al., 1990). Therefore, spinules could indicate terminals that exhibit a 
higher level of activity.  
We also found that the synapses formed by pulvinocortical terminals are more 
complex (perforated or multiple) than those formed by geniculocortical terminals, and 
whereas pulvinocortical terminals do not contact any GABAergic profiles, approximately 
28 
 
9% of geniculocortical terminals contact GABAergic profiles. Finally, we found that the 
horizontal orientation of layer IV geniculocortical terminals is quiet distinct from the 
more vertically oriented pulvinocortical terminals. Thus, future studies are necessary to 
determine the functional distinction between these projections, our results clearly 
suggest that the organization of thalamocortical synapses are quite different in the 






Figure 2.1 Schematic of dorsal lateral geniculate nucleus (dLGN) and pulvinar 
projections to the cortex in tree shrew. dLGN consists of 6 layers. Layers 1 and 4 of the 
tree shrew dLGN receive input from the ipsilateral retina, while layers 2 and 5 receive 
input from the contralateral retina. Layers 1, 2, 4, 5 and 6 project to layer IV of the 
striate cortex, while layers 3 and 6 project to layers I-III. Layer IV is divided into two 
sublayers IVa and IVb. IVa sublayer receives inputs from dLGN layers 1, 2 whereas IVb 
receives projections from layers 4 and 5. The dLGN projections to Iva arise in layers 1 
and 2 and relay input from ON-center ganglion cells, whereas projections to IVb come 
from layers 4 and 5 and receive their retinal input from OFF-center ganglion cells. 
Pulvinocortical terminals innervate layers I-IV of the temporal cortex. Pc – central 















Figure 2.2 The location of virus injection in the dLGN. Expression TdTomato (red) in 
dLGN cells and terminals after an AAV injection in layer 1 of the dLGN. The tissue was 
stained for vGLUT2 (green). (A) After the virus injection, TdTomato expression was 
primarily limited to the most medial layer of the dLGN-layer 1 and labeled terminals in 
layer IVa of V1 by anterograde transport (B). vGLUT2-containing geniculocortical 
terminals are seen only in layer IV of V1; areas labeled by both TdTomato and vGLUT2 

















Figure 2.3 The location of BDA tracer injections in the dLGN. (A) BDA injection site in 
layer 5-6 of dLGN, PUL – pulvinar; OT – optic tract; scale bar = 250 µm (B) 
Distribution of geniculocortical terminals labeled by BDA in layer IVb and sparsely in 
III. Geniculocortical terminals are distributed in distinct laminae oriented parallel to 
the striate cortex surface. (C) BDA labeled terminals after injection in layer 5 labeled 
geniculocortical terminals in layer IVb and III of V1. The layers of V1 are numbered I 






















Figure 2.4 The micrographs illustrate the distribution and morphology of 
pulvinocortical terminals in the temporal cortex, and geniculocortical terminals in V1. 
Geniculocortical terminals are distributed in distinct laminae oriented parallel to the 
striate cortex surface (A), while pulvinocortical terminals are mostly oriented 
perpendicular to the temporal cortex surface (B). Geniculocortical terminals form 
dense terminal clusters in layer IV (C), while pulvinocortical terminals are distributed 
along the length of axons that span layers IV-I (D). Scale bar in A = 100 µm and also 










Figure 2.5 Confocal image of TdTomato and vGLUT2 labeled terminals co-localization. 
(A) Terminals containing vGLUT2 are shown in green. (B) Terminals labeled by 
TdTomato are shown in purple. (C) Shows co-localization of terminals from (A) and (B) 
in white.  (D) Higher magnification example of co-localized terminals (white) labeled by 
vGLUT2 (green) and TdTomato (purple). 19.63 ± 1.6% of the TdTomato-labeled axons 


































Figure 2.6 Micrograph of geniculocortical terminal connection in layer IVa of V1. 
Geniculocortical terminals (A) are larger than pulvinocortical terminals (B, C) and 
contain spinules (asterisks) that are not found within pulvinocortical terminals. Both 
primarily contact (white arrows) nonGABAergic dendritic spines that occasionally 





















Figure 2.7 Mean size of geniculocortical terminals (GC) in layer IV sublayers of V1. The 
columns compare mean size of GC terminals labeled either by TdTomato or vGLUT2 in 
sublayers IVa or IVb of V1. Mean size, µm2. GC labeled by TdTomato in IVa, n = 100; 















Figure 2.8 GABA-content in synaptic targets of geniculocortical terminals (GC) in layer 
IV sublayers of V1. Graph shows the content of GABAergic versus non-GABAergic 
postsynaptic contacts of GC terminals labeled either by TdTomato or vGLUT2 in the 
sublayers IVa and IVb of V1, percent, % total. The majority of postsynaptic dendrites 
contacted by the labeled terminals were non-GABAergic in both sublayers. See results 
for details of GABA classification. GC labeled by TdTomato in IVa, n = 100; GC labeled 
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Figure 2.9 Percentage of spine apprati-containing postsynaptic profiles in each type of 
synaptic contact. Complex types of contacts (perforated or multiple), although less 
frequently found, were more likely to contain spine apparatus. Total number of each 
type of contact and percent, % of spines containing spine apparatus are shown. (A) 
Spine apparatus content in synapses with simple type of contact, n = 222. (B) Spine 
apparatus content in synapses with perforated type of contact, n = 101. (C) Spine 
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Figure 2.10 Comparison of pre- and postsynaptic sizes of geniculocortical (GC) versus 
pulvinocortial (PC) terminals. Open yellow squares represent GC terminals and filled 
black triangles represent PC terminals. The graph demonstrates the distribution of pre- 
and postsynaptic sizes of GC terminals in V1 and PC terminals in temporal cortex. The 
PC terminals are primarily clustered in the lower left portion of the graph, implying 
that the pre- and postsynaptic profiles have a small area, whereas GC terminals are 




































ALTERATION OF SYNAPTOPODIN AND ZINC TRANSPORTER 
TYPE 3 PROTEIN LEVELS AFTER ZINC PRECIPITATION IN WILD 
TYPE AND TRANSGENIC MODEL OF ALZHEIMER’S MICE 
CONTAINING SWEDISH, DUTCH AND IOWA MUTATIONS 
Introduction 
Epidemiological studies indicate that people with increased cognitive and 
physical activity have a reduced chance of developing Alzheimer’s disease (AD) (Wilson 
et al., 2002; Abbot et al., 2004; Larson et al., 2006; Friedland et. al, 2004; Helzner et al., 
2007; Valenzuela et al., 2012). These investigations suggest that neuronal activity may be 
protective against Alzheimer’s disease progression and studies of transgenic mouse 
models of AD support this hypothesis. When such transgenic mice are placed into 
enriched environments, they show significantly lower cognitive decline when compared 
to controls (Arendash et al, 2004, Arendash et al., 2007; Costa et al., 2007). These effects 
were especially pronounced when the enriched environment was introduced before the 
onset of amyloidogenesis (Verret et al., 2013). When enriched housing was introduced at 
later stages of amyloidogenesis in some severely affected strains no working memory 
improvement was detected (Wirths et al, 2012). Several studies also showed that an 
enriched environment reduced beta-amyloid plaque burden in the brains of different 
transgenic models of AD (Keyvani et al., 2006; Arendash et al., 2007; Sisodia, et al., 
2005). However, the mechanisms underlying the influence of different neuronal activity 
levels in the progression of Alzheimer’s pathology still remains unclear.  
The beta-amyloid plaques and neurofibrillary tangles, two major morphological 
hallmarks of AD, affect only telencephalic parts of the brain and they develop in a certain 
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sequence. Plaques and tangles first develop in the enthorhinal cortex and subiculum and 
then the distribution of plaques and tangles slowly progresses to involve whole 
telencephalon, with their presence noted in  neocortex only during the most advanced 
stages of AD (Braak, 1993, Braak et al., 2006). The affected neurons in these areas are 
primarily those that connect to other telencephalon areas; rarely can one identify 
neurofibrillary tangles or plaques in telencephalic neurons that project to the parts of the 
brain other than telencephalon (Braak, 1993, Braak et al., 2006).   
The very same areas affected by Alzheimer’s pathology are distinguished by the 
presence of glutamatergic synaptic terminals that contain zinc ions and dendritic spines 
that contain a lamellar arrangement of smooth endoplasmic reticulum known as the 
spine apparatus. One of the major structural proteins present in the spine apparatus is 
synaptopodin (Mundel et al., 1997; Deller et al., 2003) (figure 3.1). Both zincergic 
terminals and dendritic spines are thought to be very plastic; changes in neuronal 
activity result in corresponding changes in zinc accumulation as well as spine density 
and spine morphology (Chen et al., 2000; Brown and Dyck 2005; Segal 2005; Yang et al 
2008; Corson et al., 2009). Changes in spine morphology and density are postulated to 
be structural correlates of plasticity involved in higher cognitive functions such as 
learning and memory (Matus, 2005; Hyman et al., 2007).  
A decrease in spine density is thought to be one of the earliest structural changes 
affecting brains in AD pathology.  The exact causes of the spine loss are not known, but 
an understanding of activity-dependent mechanisms underlying spine retraction is 
important for the development of potential treatment options. The co-localization of 
zincergic terminals, spines with spine apparati and beta-amyloid plaques combined with 
the evidence of zinc accumulation in the brain areas deprived of the neuronal activity 
(Brown and Dyck, 2002; Land and Shamalla-Hanna, 2002; Dyck et al., 2003) led to the 
hypothesis of zinc involvement in restructuring of spine morphology. The evidence of 
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zinc along with copper directly participating in beta-amyloid aggregation (Bush et al., 
1994; Ha et al., 2007; Bush, Tanzi, 2008; Palumaa, 2009) further supports this 
hypothesis of zinc homeostasis as an important link in AD pathophysiology. 
Zinc in the brain 
As reviewed by Sensi et al., 2009, 2012, zinc, in its free ionic form, is present 
within synaptic vesicles at glutamatergic nerve terminals and is synaptically released 
during neuronal activity. One of the major roles of zinc in the brain seems to lie in its 
participation in synaptic plasticity through the interaction with N-methyl-D-aspartate 
(NMDA) glutamate receptors (Paoletti et al., 1997; Rachline, 2005). Co-release of zinc 
and glutamate in the mossy fibers of hippocampus (the area most abundantly filled with 
zinc), was shown by Qian and Noebels, 2005. Zinc in the hippocampus was shown to be 
very important for long-term potentiation processes through targeted interactions with 
numerous proteins, including ZnR (GPR39) (Besser et al., 2009), TrkB (Li Y, 2001; 
Huang et al., 2008; Nagappan et al, 208), NMDAR2b (Paoletti et al., 2009), and p75 
(NTR) (Lee et al., 2008; Adlard et al., 2010). Thus, modulation of neuronal excitability 
and participation in synaptic plasticity underlying formation of memory and learning 
appear to be one of the major roles of zinc in the brain function.  
Despite zinc’s crucial role in the brain, high levels of it can be neurotoxic. 
Alterations of zinc homeostasis have been shown to be involved in neuronal injury 
resulting from epilepsy, ischemia, and brain trauma as well as neurodegenerative 
diseases such as Alzheimer's disease (Capasso et al., 2005, Frederickson et al., 2005, 
Mocchegiani et al., 2006; Frazzini 2006; Galasso and Dyck, 2007; Nakashima and Dyck, 
2008).   
Zinc Transporters 
There are several types of zinc transporters in the brain as reviewed by 
Nakashima and Dyck, 2008. Zrt-Irt-like proteins (ZIP) move zinc into the cytoplasm 
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from the extracellular space and organelles (Gaither and Eide, 2001). To transport zinc 
out of the cytoplasm, mammals use 10 types of zinc transporter proteins known to date 
(Cousins et al., 2006). ZnT1 transports zinc out of the cytoplasm, ZnT2 and 4 participate 
in zinc transport into the endosomes and lysosomes and ZnT-5, 6, 7 are found on the 
Golgi apparatus. The roles of ZnT-8, 9 and 10 are not well studied yet. All of the above 
transporters are ubiquitous and found not only in the brain but also in other tissues. 
However the zinc transporter type 3 (ZnT3) is exclusively found in the brain and testis 
and it is responsible for the movement of zinc from the cytoplasm into synaptic vesicles. 
The distribution of ZnT3 expression is correlated with the distribution of 
vesicular zinc in the brain (Palmitter et al., 1996; Lee et al. 2011). Because ZnT3 is the 
only known protein that regulates vesicular zinc, it was proposed to be an important for 
cognitive function (Adlard et al., 2010). In experiments with transgenic ZnT3-knockout 
mice, it was shown that these mice lacked normal vesicular zinc content (Cole et al., 
1999). Moreover, these mice exhibited cognitive deficits similar to those found in 
Alzheimer’s disease but only starting at the age of 6 months. Other authors reported 
deficiency in social and object recognition memory in 3-4 month old  ZnT3-knockout 
mice (Shumyatsky et al., 2011). Adlard et al. (2010) showed that the level of ZnT3 
steadily decreases from about two months of age in wild type mice, after 48 years in 
humans, and large decreases are detected in transgenic mouse models of AD.   
Zinc and Alzheimer’s disease 
Because zinc facilitates the precipitation of beta-amyloid (Aβ), its role in the 
pathogenesis of AD has been investigated intensively. The soluble Aβ monomers released 
by neuronal activity from synaptic terminals are constantly degraded by matrix 
metalloproteinases, but whenever these monomers bind zinc in the vicinity of a terminal, 
they form oligomers resistant to degradation (Bush et al., 1994; Garai et al., 2006; Sensi 
et al., 2009). Even zinc deficiency ultimately causes zinc retention by the brain and has 
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been shown to increase amyloid plaque burden in transgenic mice (Takeda et al., 2001; 
Stoltenberg et al., 2007). Extracellular amyloid plaques have also been shown to be 
enriched in zinc (Lovell et al., 1998; Lee et al., 1999; Miller et al., 2006; Adlard et al., 
2008). Double-transgenic mice overexpressing Aβ and knocked-out by ZnT3, abolish 
interstitial (Lee et al., 2002) and vessel-wall (Friedlich et al., 2004) amyloid pathology. 
In addition to these potential roles in plaque formation, zinc plays an important 
physiological role in cognitive processes (as described above). Thus, the rapid trapping of 
Zn2+ by amyloid-beta plaques could affect the potentiation of glutamatergic synaptic 
connections and contribute to cognitive deterioration (Sensi et al., 2011).   
Previous attempts to manipulate zinc levels lead to discovery of the drug with the 
name PBT2 that is a derivative of the antifungal medication clioquinol. PBT2 is able to 
precipitate zinc and copper ions in the brain and reduced amyloid plaque burden in 
several types of AD transgenic mice (Adlard et al., 2008). Currently this drug is in phase 
II clinical trials and has shown to improve cognition in Alzheimer’s disease patients 
(Lannfelt et al., 2008; Faux et al., 2010). Further investigations of the mechanism of this 
drug showed that in the brains of Alzheimer’s disease transgenic mice treated with PBT2 
there was a significant increase in dendritic spine density, whereas treatment of control 
mice with PBT2 did not affect spine density (Adlard et al., 2011). These results lead to the 
possible zinc effect on spine stability in the brain that was further supported by the work 
of other investigators, who looked at the changes in dendritic spines in Alzheimer’s 
pathology. 
Amyloid precursor protein and spine motility 
The early stages of memory loss in AD are thought to be related to the loss of 
dendritic spines and their presynaptic connections. There is a significant decrease in 
spine density in the cortex and hippocampus of human AD brains and brains of several 
transgenic mouse models of AD (Catala et al., 1988; Davies et al., 1987; de Ruiter et al., 
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1987; Reddy, 2005; Spires-Jones et al., 2007). The events leading to this loss are unclear, 
but amyloid precursor protein (APP) is suggested to be a key protein involved in the 
modulation of dendritic spine density.  
APP is a transmembrane protein with a large extracellular domain that is thought 
to interact with adhesive junctions between neurons and/or the extracellular matrix that 
surrounds neurons. Cleavage of APP with certain enzymes results in the formation of 
beta-amyloid which is the key component of amyloid plaques. Forms of familial AD with 
early onset are mostly associated with mutations in genes involved in the processing of 
APP. Enzymatic cleavage of APP leads to reduced spine stability and the removal of 
endoplasmic reticulum (spine apparatus) from spines (Storey et al, 1996; Spires-Jones et 
al., 2007; Ng and Toresson, 2008). It has been shown that direct application of beta 
amyloid to hippocampal slice cultures is able to transform mushroom-shaped spines to 
stubby spines, and decrease spine density (Tackenberg and Brandt, 2009; Wei et al., 
2010). APP is cleaved by a number of different enzymes, but chief among these are the 
cell surface metalloproteinases, which are catalyzed by zinc (Adlard and Bush, 2006). 
Also, as mentioned earlier, the distribution of zincergic terminals is mirrored by the 
distribution of dendritic spines that contain spine apparati uniquely identified by their 
association with the actin-binding protein synaptopodin (Mundel et al, 1997). Although 
neurons with dendritic spines are found in most areas of the brain, only spines within 
the telencephalon contain spine apparati (Deller et al., 2003; Vlachos et al., 2009). 
Possibly, zinc release from less active terminals triggers the cleavage of APP and, 
as a result, dissolution of the spine apparatus, and transformation of mushroom-shaped 
spines to smaller, more mobile spines. This process could be beneficial in the normal 
brain for mediating the plasticity necessary for the formation of new synapses underlying 
learning and memory. In AD, however, either spine retraction is increased, or spine 
formation is decreased, so that there is an overall loss of spines and synaptic 
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connections. To investigate this interaction we looked at the ways to manipulate zinc 
levels in the brain and trace the effect of this on dendritic spines and zincergic terminals 
by measuring synaptopodin levels as well as changes in ZnT3 levels. We decreased zinc 
levels by precipitating it with sodium selenite. This manipulation results in the formation 
of nanocrystals of zinc selenite and thereby, decreases the active free ion availability of 
zinc (Danscher and Stoltenberg, 2006; Doering et al., 2010). 
  
Materials and methods 
A total of 54 mice were used for these experiments. Of these, 27 mice were wild 
type C57BL/6 and 27 mice were the transgenic model of Alzheimer’s disease: C57BL/6-
Tg(Thy1-APPSwDutIowa)BWevn/Mmjax  (TgSwDI; this model expresses neuronally 
derived human amyloid β-precursor protein, APP gene, 770 isoform, containing the 
Swedish K670N/M671L, Dutch E693Q and Iowa D694N mutations, under the control of 
the mouse thymus cell antigen 1, theta, Thy1, promoter). Each group of WT or TgSwDI 
mice were further subdivided into 3 groups of  9 mice each that were used at 1, 4 and 6 
months of age (for the examples of pathology at different ages refer to the results in 
chapter IV). 
For each age and strain group, 3 mice were anesthetized with Avertin (0.01 ml/g; 
stock made as a mixture of 5 gm of tribromoethanol with 5 ml of tert-amyl alcohol; 
working solution is 2.5% of stock), and as soon they did not show any reflexive responses 
they were immediately decapitated to collect tissue for western blots. Another group of 3 
mice was anesthetized with avertin and then received an intraperitoneal injection of 
sodium selenite (0.05% in distilled water; 0.003ml/g) and were sacrificed after 1 hour 
for tissue collection. The final 3 mice received an intraperitoneal injection of sodium 
selenite and were sacrificed after 3 hours.  
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After each mouse was decapitated, the brain was rapidly removed and after quick 
rinse in a 0.1M phosphate buffer, pH 7.4 (PB) was placed into Alto Coronal Brain Matrix 
(AL-1175; Mouse 45-75Gram; Acrylic; 1mm) and cut into several 1 mm thick coronal 
slices using a razor blade. Selected slices were placed on slides and the parietal cortex 
and hippocampus from the one side of this coronal section were dissected and 
immediately immersed in liquid nitrogen. In some cases the cerebellum was also 
removed as a control. Tissue then was prepared for western blot techniques as described 
below. All the methods used were approved by the University of Louisville Animal Care 
and Use Committee and conform to the National Institutes of Health guidelines.  
Western blots 
The frozen tissue was prepared for electrophoresis. Each piece of tissue was 
homogenized in Triton lysis buffer (20 mM of 1M Tris, pH 6.8; 137 mM of 5M NaCl; 25 
mM of 0.4M β-glycerophosphate, pH 7.14; 2mM of 0.2M Na pyrophosphate; 2mM of 
0.5M EDTA; 1mM of 0.1M of Na3VO4; 1% of 10% triton X-100; 10% of 50% glycerol; 1X 
of 200X protease inhibitor cocktail; 0.5mM of 1M dithiothreitol; 1mM of 100mM 
phenylmethanesulfonyl fluoride; and double distilled water to needed volume) and 
sonicated with ultra cell disruptor Microson (Misonix, Inc.) on ice. The lysates were then 
centrifuged at a speed of 13000 rpm for 30 minutes and the supernatant was separated 
from the pellet by pipette. The supernatant was then used for protein estimation and 
loading onto gels. To estimate the protein concentration into each sample, the series of 
bovine serum albumin (BSA) was used. For that, each sample was diluted 1:10 with 
double distilled water and loaded into the 3 wells 96-well plate by 10 µl per each sample. 
The six increasing concentrations of 1mg/ml BSA were also loaded into the slots on the 
same sample plate. Further, 200µm of the Bio-Rad Protein Assay (Bio-Rad Laboratories, 
Inc., Hercules, CA) added in each slot. The plate then left for 5 minutes and protein 
concentration estimated with spectrophotometer SpectramaxPlus (Molecular Devices) 
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and software (SoftMax Pro, Molecular Devices). Using Microsoft Excel software, the 
linear plot was created based on the results from spectrophotometer and concentration 
of protein for 20 micrograms per sample calculated. Then, 200 µl of Bio-Rad Laemmli 
sample buffer (65.8 mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% (w/v) glycerol, 0.01% 
bromophenol blue) and 50 µl of 2-mercaptoethanol in double distilled water were added 
to complete the 15 µl mixture. This samples then were centrifuged for 5 minutes and 
placed into the hot plate at 95ºC for 10 minutes. The ready samples were spun once 
again for 5 minutes and loaded onto gels. 
The premade Bio-Rad gels were used for this experiment (Mini-PROTEAN® 
TGX Any kD Stain-Free™ 10-well precast gels with SDS-PAGE accessories, Bio-Rad). 
Samples were loaded 15 µl per well and Bio-Rad Kaleidoscope™ protein standards were 
used for detection of molecular weight on the transfer membrane. Molecular weight for 
synaptopodin is 100 kDa, for ZnT3 it is 48 kDa and molecular weight of GAPDH is 39 
kDa.  Gels were placed into the Bio-Rad running chamber CRITERION™ Cell and after 
electrophoresis in Bio-Rad 10x Tris/Glycine/SDS running buffer at 200V was done, 
proteins from the gels were transferred onto the membrane using Bio-Rad Trans-
Turbo® Blot™ transferring device, and, after staining with appropriate antibodies, 
developed using ChemiDoc™ MP Imager (Bio-Rad) and bands were assessed using 
Image Lab™ software.  
The following antibodies were used for western blotting in this experiment. 
Mouse anti- synaptopodin (1:2000, Synaptic Systems Inc.), rabbit anti-zinc transporter 
type 3 (anti-ZnT3) (1:2000, Synaptic Systems Inc.), and mouse anti-glyceraldehyde-3-
phosphate dehydrogenase, clone 6C5 (anti-GAPDH) (1:2000, Millipore) as a 
housekeeping protein. Following transfer from the gels to the membrane, it was washed 
in 1% phosphate buffer with saline and Tween20 (PBS-T) solution three times (20 ml 
0.5M PB, 9g NaCl, 1 ml of Tween20) and then places in 5% non-fat milk solution in PBS-
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T for 1 hour for blotting non-specific for out antibodies proteins. After 1 hour, membrane 
was placed into 1:2000 solution of anti-synaptopodin in milk or 1:2000 anti-ZnT3 
solution at 4ºC overnight. Next day, after washing membrane 3 times in PBS-T, the 
1:2000 solution of secondary antibodies in milk were applied. Anti-mouse IgG 
horseradish peroxidase conjugated, SC-2768 (made in goat, 1:2000; Santa Cruz 
Biotechnology Inc.) for anti-synaptopodin primary and anti-rabbit IgG horseradish 
peroxidase conjugated, SC-2054 (made in goat, 1:2000; Santa Cruz Niotechology Inc.) 
for anti-ZnT3 for 1 hour and after 3 washes in PBS-T, the membrane was ready to be 
examined in ChemiDoc™ MP Imager. To reveal bands, two commercially available 
solutions from Bio-Rad were used (Clarity Western ECL Substrate, Bio-Rad) that were 
mixed right before use and applied onto the membrane for 30 seconds before placing the 
membrane into the developing chamber.  
For the control of protein content and loading differences, the staining of 
membrane for housekeeping protein GAPDH was used. The process of staining was 
similar to the described above.  
Using Image Lab software, the density of each band (synaptopodin or ZnT3) was 
measured and divided by the density of GAPDH in the corresponding well to adjust for 
the differences in the protein content among wells (GAPDH is supposed to be constantly 
expressed in every animal). Further, the results were grouped in the Excel file and 
forwarded for statistical analysis to the KSCIRC biostatistics core. 
Data analysis 
To analyze the data, statistical analyses were performed using one-way ANOVA 
procedures and independent t-tests were used to compare the differences in 
synaptopodin and ZnT3 levels between the wild type mice and transgenic mice models. 
Also, to analyze the differences across the animals including all three parameters (age, 
group and time) 3-way ANOVA was used with subsequent use of two-way ANOVA by age 
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and group and post hoc t-test comparisons by age and then group. All statistical analyses 
were performed using IBM SPSS, version 20 software. The graphs were plotted using 
Sigma Plot, version 11.  
 
Results 
Figure 3.2 shows the bands that were received after developing the image from 
the membrane. ZnT3 and synaptopodin were detected in the cortex and hippocampus, 
but not the cerebellum, confirming previous immunocytochemical studies (Paoletti et al., 
2009). After the appropriate analysis methods were employed (described above) the 
following results were obtained (Figure 3.3, 3.4 and 3.5).  
Alterations of synaptopodin after zinc precipitation in one month old WT 
and TgSwDI mice 
We initially investigated whether zinc precipitation affected synaptopodin levels 
in 1-month old mice when the plastic and metabolic processes in the brain are, 
presumably, at the highest levels and the Alzheimer-like pathology had not yet developed 
in the TgSwDI mice. As seen in the figure 3.3, without sodium selenite injection, the 
levels of synaptopodin were higher in the control animals (WT, black column, 0 time 
point) than in the transgenic mice (transgenic, white column, 0 time point) but this 
difference did  not reach statistical significance for either  cortex or hippocampus. After 
zinc was precipitated with sodium selenite, the level of synaptopodin was measured after 
1-hour and 3-hour intervals in WT and TgSwDI mice. However,   there was no 
statistically significant difference in the levels of synaptopodin in the cortex or 
hippocampus of any of these groups of animals. It is worth noting that in all groups 
synaptopodin levels were consistently higher in WT versus TgSwDI animals but, again, 
this difference did not reach statistical significance.  
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Alterations of synaptopodin after zinc precipitation in four month old WT 
and TgSwDI mice  
We next conducted our experiment in more mature, 4 month old mice. According 
to our data (reported in the next chapter) and that reported by Nostrand et al., 2004, 
with our transgenic mouse model, the pathological signs of Alzheimer’s disease can be 
detected in 4-month old TgSwDI mice (figure 4.3 in chapter IV). Thus, we considered 
this age to be the most appropriate time point for investigating whether the disease 
progression changes zinc metabolism and whether this has an effect on synaptopodin 
levels. As seen in the figure 3.4, similar to our findings for 1 month old tissue, the level of 
synaptopodin in 4 month old WT brains was generally higher than in 4 month old 
TgSwDI brains. However, this difference was not statistically significant. There also were 
no statistically significant differences in the levels of synaptopodin after sodium selenite 
treatments in 4 month old animals. 
Alterations of synaptopodin after zinc precipitation in six month old WT and 
TgSwDI mice  
By 6 months of age, the brains of our transgenic mice displayed distinct areas of 
beta-amyloid deposits, predominantly in the hippocampus (figure 4.3 in chapter IV).  As 
illustrated in Figure 3.5, we found that, as in 1 and 4 month old mice, the cortex of 6 
month old WT mice had higher levels of synaptopodin when compared to the cortex of 6 
month old TgSwDI mice. This difference reached significance at 1 hour post sodium 
selenite treatment (p-value <.01). However, the opposite result was found in the 
hippocampus. For this structure, at all three time points, TgSwDI mice showed higher 
synaptopodin levels when compared to WT mice and this difference was statistically 
significant for the 1-hour and 3-hour post sodium selenite time points (both p-value < 
.01). Moreover, in TgSwDI mice, there was a significant increase in synaptopodin levels 1 
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hour after the injection of sodium selenite when compared to the levels of synaptopodin 
in mice without sodium selenite injection (time point 0; p-value <.01).  
Comparison of synaptopodin alterations after zinc precipitation in WT and 
TgSwDI at different ages 
After the statistical analysis was completed for each age group separately, we next 
examined whether there were differences in synaptopodin levels across the age groups. 
We used a 3-way ANOVA and post hoc t-test. The results of this analysis indicate that 
synaptopodin levels in both the cortex and hippocampus were higher in 4 month old WT 
mice than in 1- or 6-month old WT mice (both p<.01) at all time point related to sodium 
selenite injection. In TgSwDI mice, synaptopodin levels in the cortex were higher in 4-
month old animals when compared to 1- and 6-month old animals at the 0- and 3-hour 
time points (both p<.01) and synaptopodin levels in the hippocampus were higher in 4 
month old animals compared to 1 month old animals at the 0- (p<.01) and 3-hour 
(p<.01) time points.   
Alterations of ZnT3 after zinc precipitation in one month old WT and 
TgSwDI mice  
ZnT3 is essential for the accumulation of zinc within synaptic vesicles (Palmiter 
et al., 1996; Skangiel-Kramska et al., 2005). Therefore we assessed potential changes in 
the levels of this transporter related to zinc precipitation or differences in WT versus 
TgSwDI animals. As illustrated in figure 3.3 there were no significant differences in ZnT3 
levels in the cortex or hippocampus of one month old WT animals compared to TgSwDI 
animals, even though the absolute ZnT3 levels were consistently higher in the TgSwDI 
animals.  The precipitation of zinc with sodium selenite failed to alter ZnT3 levels in any 
statistically significant manner in one month old WT or TgSwDI animals. 
Alterations of ZnT3 after zinc precipitation in four month old WT and 
TgSwDI mice  
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When ZnT3 levels were examined in 4 month old mice, there was a significant 
differences noted between WT and TgSwDI in both the cortex and hippocampus at 0- 
and 1-hour time points (figure 3.4). The TgSwDI showed significantly higher ZnT3 levels 
at these time points (all p<.01). Again, there was no statistically significant change in 
ZnT3 levels in WT or TgSwDI when compared at different time points after sodium 
selenite treatment. 
Alterations of ZnT3 after zinc precipitation in six month old WT and TgSwDI 
mice  
As illustrated in figure 3.5, the analysis of tissue collected from 6 month old mice 
revealed significantly higher levels of ZnT3 in the hippocampus of TgSwDI animals 
compared to the hippocampus of WT animals only at 1-hour time point (p<.01). All other 
groups were not found to be significantly different. Thus, significant differences in ZnT3 
levels that we observed in 4 month old mice were lost as the animals aged. Sodium 
selenite treatment did not alter ZnT3 levels significantly in 6 month old animals.  
Comparison of ZnT3 alterations after zinc precipitation in WT and TgSwDI 
at different ages 
Repeating the post hoc t-test comparison to test for differences in ZnT3 levels 
across age groups, we discovered that there was no difference in ZnT3 levels in WT mice 
of different ages, but there was a significantly higher level of ZnT3 in both the cortex and 
hippocampus of 4 month old TgSwDI mice when compared to either 1 month old or 6 
month old TgSwDI mice (for no sodium selenite treatment and for 1 hour post sodium 
selenite treatment, all p<0.01). Also, the cortex of 6 month old untreated TgSwDI mice 
contained higher levels of ZnT3 levels than the cortex of untreated 1 month old TgSwDI 






Zinc precipitation in the brain is known to improve cognitive functioning in 
TgSwDI mice and humans with AD, but the exact mechanism by which zinc participates 
in AD and cognition is not clear. Our hypothesis was that zinc is not only released from 
plaques as one of the proposed mechanism of PBT2 action (Adlard et al., 2008), but its 
precipitation by selenite might lead to the preservation of mature dendritic spines, which 
are shown to be progressively lost in Alzheimer’s disease (Catala et al., 1988; Davies et 
al., 1987; de Ruiter et al., 1987; Reddy, 2005; Spires-Jones et al., 2007). The 
preservation of mature dendritic spines could supply the necessary anatomical basis for 
potentiation of synapses, and perhaps account for the improvement in cognitive behavior 
previously reported following zinc chelation or precipitation (Adlard et al., 2008; 
Lannfelt et al., 2009; Faux et al., 2010).  
In fact, spine density has been reported to increase after zinc chelation therapy 
(Adlard et. al, 2011), but the types of spines that are increased have not been evaluated. 
In the present study, we wanted to test whether zinc precipitation would have an effect 
on the most mature dendritic spines, those that contain a spine apparatus and the 
protein synaptopodin. Our hypothesis was that precipitation of zinc would lead to 
increases in synaptopodin. We also wanted to see how ZnT3 levels would change with 
zinc precipitation to assess whether free zinc levels regulate levels of this transporter. 
Lastly, we wanted to determine whether ZnT3 or synaptopodin levels were altered in our 
TgSwDI mice relative to WT mice, and whether ZnT3 or synaptopodin levels change with 
age or the progression of AD pathology. 
Zinc and synaptopodin 
The results of our experiments showed that the precipitation of free zinc into 
zinc-selenite nanocrystals did not significantly affect synaptopodin levels in most of the 
animals tested. However, there was a significant increase in synaptopodin levels in the 
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hippocampus of 6 month old TgSwDI after 1 hour of zinc precipitation relative to 
TgSwDI mice without zinc precipitation. These results could be interpreted in several 
ways. The first and the most straightforward possibility, is that the free zinc pool does 
not affect the restructuring of dendritic spines directly either in physiological or 
pathological conditions. The increase in synaptic density demonstrated by Adlard et al 
(2011) after the zinc chelator use could be explained by mechanisms related to the effect 
of this chelator on zinc that is bound to amyloid plaques. Decreasing available zinc could 
lead to the decreased formation of new plaques, or the destabilization of previously 
formed plaques to form more soluble oligomers (Ritchie et al., 2003; Dukes et al., 2008; 
Sensi et al., 2009). This could subsequently facilitate physiological spine re-growth, that 
is otherwise inhibited by beta-amyloid (Spires-Jones, 2007; Koffie et al., 2009). That 
would explain the increase in spine density following zinc precipitaiton in TgSwDI but 
not WT mice found by this research group. This might also explain why we saw an 
increase in synaptopodin after zinc precipitation only in our oldest age group and only in 
TgSwDI mice.  
One reason that our results differ from those of Adlard et al. (2011) could be the 
fact that synaptopodin is present only in the most mature spines, while the spine density 
increase reported by Adlard’s group was not differentiated by spine maturity. Another 
possibility is that the 1- and 3-hour time points used in our experiments were not long 
enough for mature spines to be formed. The profound effect of sodium selenite toxicity 
on our experimental animals would not allow us to conduct our investigation at time 
points longer than 3 hours, while Adlard’s group used a less toxic chelator therapy for 11 
days. Moreover, they used 4-month and 14-month age groups and a different transgenic 
model (Tg2576), while our experiments were conducted in younger mice of a different 
strain.  The only significant change we detected in our zinc precipitation experiments 
was in the hippocampus of 6-month old TgSwDI. As presented in the next chapter, we 
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began to detect pathological changes only in the hippocampal region of TgSwDI at this 
age. Therefore, we may have found more significant changes if we had used older 
TgSwDI mice. Lastly, unfortunately, our sample size was small. We conducted a power 
analysis to determine whether changes might be detected if we increased our 
experimental groups. However, this analysis revealed that the necessary increase in 
animal numbers was not feasible.  Therefore at this point, we must conclude that our 
results to date do not support our theory that free zinc levels impact mature dendritic 
spine development or preservation.   
Zinc and ZnT3 
When we analyzed our data to determine whether the precipitation of zinc 
affected levels of the zinc transporter type 3 levels (ZnT3). We hypothesized that the 
precipitation of zinc might up-regulate ZnT3 in response but we failed to detect any 
significant changes in the levels of ZnT3 protein. Possibly, the time frame of our 
experiments was not enough to change protein expression levels. On the other hand, 
previous experiments suggest dissociation in the levels of synaptic zinc and ZnT3 during 
the development of the barrel cortices of young mice. Also, neither short-term nor long-
term sensory deprivation that caused an increase in zinc levels led to changes in ZnT3 
levels in adult mice (Skangiel-Kramska, 2005). These results suggest that there may be 
other mechanisms for regulating ZnT3 expression that do not rely on total zinc levels.  
Further studies concerning this point are needed to evaluate how ZnT3 levels may 
change in response to synaptic activity and how ZnT3 levels regulate zincergic and/or 
glutamatergic transmission.  
Synaptopodin and ZnT3 in WT versus TgAD mice 
  Finally, we examined our data to determine whether synaptopodin or ZnT3 
levels were different in TgSwDI mice relative to WT mice, and whether these levels are 
age dependent. We did not detect any significant differences in the levels of 
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synaptopodin in WT versus TgSwDI until 6 months of age. At this point, several 
interesting results were noted. Despite the fact that we expected to see a decline in 
synaptopodin levels as the TgSwDI mice aged, it was in our oldest animals that we 
discovered that hippocampal synaptopodin levels actually were significantly higher in 
TgSwDI mice than in WT mice. However, these significant differences were only in the 
groups that were treated with sodium selenite, at both the 1 and 3 hour time points. This 
suggests that zinc precipitation can affect spines in older TgSwDI mice. Surprisingly, this 
effect is so strong that the synaptopodin levels in these mice were higher than that found 
in WT mice. In contrast, we did not see any differences in synaptopodin levels in the 
cortex of TgSwDI mice and WT mice, potentially because the cortex is not obviously 
affected by pathology at 6 months of age (figure 4.3 in chapter IV). Moreover, zinc levels 
are higher in the hippocampus than in any other area of the brain (figure 3.1). Therefore 
zinc precipitation may have its greatest effect on spines in the hippocampus.  
These observations are even more intriguing when considered in the context of 
the changes in ZnT3 levels detected in animals of different ages. We found that in tissue 
collected from 4 month old animals the ZnT3 levels were higher in TgSwDI mice 
compared to WT mice. This difference was very prominent in both the cortex and 
hippocampus, suggesting that vesicular zinc transport undergoes significant changes at 
an age which coincides with the appearance of the first plaques in our TgSwDI model 
(figure 4.3 in chapter IV). By the age of 6 months there were no significant differences in 
ZnT3 levels in the cortex of TgSwDI and WT mice, and ZnT3 levels were higher in the 
hippocampus of TgSwDI relative to WT animals at only one time point.  
Our data indicate that ZnT3 levels in WT mice were not different in either the 
cortex or hippocampus collected at 1, 4 and 6 months of age. In contrast, the ZnT3 levels 
were higher in tissue collected from 4 month TgSwDI mice than in tissue collected at 1 
month or 6 months of age. This suggests that normally ZnT3 levels remain relatively 
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constant, but in TgSwDI there is a surge in ZnT3 expression at 4 months of age which is 
followed by decline back towards initial 1 month levels by 6 months of age.  Further 
complicating the interpretation of our data are two previous studies that examined age 
related changes in zinc and ZnT3 levels, each of which came to a different conclusion. 
Adlard et al. (2010) found a decline in zinc and ZnT3 levels as animal aged, whereas Lee 
et al. (2012) stated that zinc and ZnT3 levels increase with age. The major difference 
between these studies was the age of the animals investigated. Adlard’s group compared 
2-8 month old mice while Lee et al compared 12-24 month old mice.  
The cause and consequences of such fluctuations in ZnT3 levels requires further 
investigation. One hypothesis is that entrapment of free zinc in the amyloid plaques 
causes its depletion for physiological purposes (Adlard et al., 2010). This idea fits very 
well with the surge of ZnT3 expression during the initial stages of plaque development. 
This surge could possibly represent an attempt to overcome a developing zinc deficiency 
at the synaptic cleft (Deshpande et al, 2009). An amplified expression of ZnT3 in AD 
might be sustained for a time, but when the increasing numbers of dystrophic neurons 
are unable to synthesize ZnT3, the level of ZnT3 would then drop. Further studies will be 
necessary to determine how ZnT3 levels are regulated during the later stages of 
Alzheimer’s pathology.  For now, we can conclude that in our TgSwDI model, major 
changes in dendritic spine maturation and zinc trafficking take place at the crucial age of 
4 months, and that the precipitation of zinc does not necessarily cause an immediate 






Figure 3.1 Zinc and synaptopodin staining of rat brain. (A) Parasaggital section of rat 
brain stained for zinc (brown) from Paoletti et al., 2009. Zinc is distributed only in the 
telencephalon. ao, anterior olfactory nucleus, am, amygdala, cp, caudate and putamen, 
h, hippocampus, s, subiculum, IV, neocortex layer 4. (B) Parasaggital section of rat 
brain stained for synaptopodin (darker stained areas). Synaptopodin distribution 




































Figure 3.2 The western blot bands from the cortex of 4-month old (A) and 6-month old 
(B) experimental animals. In the experiment, wild type (WT) and TgSwDI (Tg) mice 
levels of synaptopodin and ZnT3 were compared between the groups and after 1 hour 
(1h), 3 hours (3h) of intraperitoneal sodium selenite injection. Control animals did not 




















Figure 3.3 Synaptopodin and ZnT3 levels before and after sodium selenite treatment in 
cortex and hippocampus of 1-month old WT and TgSwDI mice. Black columns 
represent WT mice, each column, n = 3; white columns represent TgSwDI mice, each 
























Figure 3.4 Synaptopodin and ZnT3 levels before and after sodium selenite treatment in 
cortex and hippocampus of 4-month old WT and TgSwDI mice. Black columns 
represent WT mice, each column, n = 3; white columns represent TgSwDI mice, each 
column, n = 3. Significant differences (asterisks) between WT and TgSwDI were found 
in the level of ZnT3 in both cortex and hippocampus in controls and at 1-hour time 















Figure 3.5 Synaptopodin and ZnT3 levels before and after sodium selenite treatment in 
cortex and hippocampus of 6-month old WT and TgSwDI mice. Black columns 
represent WT mice, each column, n = 3; white columns represent TgSwDI mice, each 
column, n = 3. Significant differences (asterisks) between WT and TgSwDI were found 
in the level of synaptopodin in both cortex (at 1-hour) and hippocampus (at 1- and 3-
hours) and ZnT3 in hippocampus at 1-hour time point, all p-values <.01. Also, 
significant difference in synaptopodin level was found after 1-hour of sodium selenite 















BETA-AMYLOID PLAQUE FORMATION: HISTOCHEMICAL 
AND ULTRASTRUCTURAL CHARACTERISTICS IN A TRANSGENIC 
MOUSE MODEL OF ALZHEIMER’S DISEASE CONTAINING 
SWEDISH, DUTCH AND IOWA MUTATIONS  
 
Introduction 
Beta-amyloid (Aβ), or senile, plaque is a major histopathological hallmark of 
Alzheimer’s disease (AD). Extensive work by previous investigators has revealed the 
major ultrastructural constituents of amyloid plaques in human tissue (Kidd, 1963, 1964; 
Terry, 1963; Terry et al., 1964; Wisniewski and Terry, 1973). Extracellular deposits of 
amorphous material represent the core of the plaque. This core consists of β-amyloid 
fibrils, produced from amyloid precursor protein (APP) after sequential proteolytic 
cleavage by β- and γ-secretases (Kang et al., 1987; Selkoe et al., 2001; Pluta et al., 2013). 
The beta-pleated sheet structure of this protein confers the ability of it to bind to the dye 
Congo red, producing birefringence when inspected under polarized light; this is a 
defining property of the amyloid (Perl, 2010).  
When viewed with a light microscope, senile plaques are generally seen as a 
single morphological unit, but the extensively studied Aβ is not the only constituent of 
these plaques.  Although the term “diffuse plaque” is used to define extracellular 
agglomerates of Aβ fibrils with minimal adjacent neuritic dystrophy (Yamaguchi et al., 
1989), the most pronounced pathological sign of AD is characterized by abnormal 
neurites that surround an amyloid core. These abnormal neurites are composed of the 
axons or dendrites of dystrophic, dying or dead neurons that contain dense bodies, 
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membranous profiles, and packets of paired helical filaments (Perl, 2010). There is a 
significant loss of synaptic connections within these abnormal areas, and this is thought 
to be the major correlate of cognitive decline in affected AD patients (DeKosky and 
Scheff, 1990; Terry et al., 1991; DeKosky et al., 1996; Scheff and Price, 2003; Thind and 
Sabbagh, 2007; Knafo et al., 2012). The plaques that exhibit a corona of dystrophic 
neurites surrounding a central core center filled with Aβ are generally described as “core-
only plaques” or “neuritic plaques”. The term “burnt-out plaque” also occurs in the 
literature; this refers to plaques that present a dense core of Aβ without any adjacent 
cells (Thal et al., 2000). 
Reactive astrocytes and microglia are other important components of the neuritic 
plaques (Frackowiak et al., 1992; Wegiel et al., 2000; Stalder et al., 1999, 2001; Nagele et 
al., 2004). Clinical work and studies of AD animal models suggest that microglial 
activation precedes the formation of plaques or tangles (Griffin et al., 1989; Heneka et 
al., 2005; Solito and Sastre, 2012). However, after several decades of investigation, the 
role of microglia in the progression of AD is still debated. Microglial involvement in AD 
pathology could be beneficial, via clearance of Aβ, phagocytosis of damaged cells, and 
release of neuroprotective anti-inflammatory factors. On the other hand, microglial 
involvement in AD could be harmful due to excessive generation of reactive oxygen 
species (Solito and Sastre, 2012; Sierra et al, 2013).  
The distribution of senile plaques in the brain progresses in a stereotyped 
manner. Braak and Braak, 1991 first described the stages of AD pathology and this was 
modified in later work (Thal et al., 2006). According to Braak and Braak, the initial 
plaque distribution begins in the phylogenetically oldest part of the brain, the allocortex, 
which includes the olfactory bulb, entorhinal region, presubicular region, and 
hippocampal formation. As the disease progresses, plaques and tangles are found in the 
mesocortex, which includes the orbitofrontal region, cingluate gyrus and the 
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parahippocampal gyrus. In the final stages of the disease, plaques and tangles are 
distributed in the neocortex.  
The stage of Braak and Braak primarily considered the formation of neuritic 
plaques. Later investigations of plaque progression have additionally taken into account 
the formation of diffuse plaques. If diffuse plaques are considered, these are found prior 
to neuritic plaques and are first seen in the neocortex. These are generally first seen in 
the temporal cortex and from there progress to the subiculum/CA1 and enthorhinal 
regions and then other allocortical regions (Thal 2002; 2006). When compared to 
neuritic plaques, diffuse plaques are thought to be the less detrimental to cognitive 
function because they are seen even in the normally aging brains of unaffected 
individuals (Price et al., 1991; Arriagada et al., 1992). However, it is still unclear whether 
diffuse plaques represent a different pathological process or if diffuse plaques represent 
and early stage in the development of neuritic plaques.   
To begin to shed light on this issue, we examined the development of plaques in a 
transgenic mouse model of AD. We use the triple mutant C57BL/6-Tg(Thy1-
APPSwDutIowa) BWevn/J. These transgenic mice express neuronally derived human 
amyloid beta-precursor protein, APP gene, 770 isoform, containing the Swedish 
K670N/M671L, Dutch E693Q and Iowa D694N mutations, under the control of the 
mouse thymus cell antigen 1, theta, Thy1, promoter. The major efforts in creating 
transgenic mouse models of AD have been directed to the overexpression of APP, 
mutated to reflect the known APP mutations that are seen in familial forms of AD that is 
referred as “human” APP (hAPP). The APP gene contains 19 exons 7, 8 and 15 of which 
are subjects to alternative splicing. They form different APP isoforms designated by the 
number of amino acids (Mucke et al., 1995). The longest of these isoforms, APP770, was 
targeted in our model to introduce three mutations, named after the origin of the 
families that were first discovered to carry each of those mutations. First, Swedish 
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K670N/M671L, with the altered codons 670/671, is a double mutation in the site coding 
for two amino acids immediately preceding the β-secretase cleavage site; this induces the 
increased cleavage of APP by β-secretase and results in more production of Aβ40 and 
Aβ42  (Selkoe et al., 2001). Second, Dutch E693Q (the number corresponding to APP770 
isoform numbering; also known as Dutch E22Q if considering the Aβ sequence 
numbering) is a single point mutation which leads to an increase in aggregation rates of 
Aβ by lowering the barrier for Aβ monomer deposition into a fibril (Levy et al., 1990; 
Baumketner et al., 2008). Introduction of this mutation also leads to the development of 
pronounced cerebrovascular Aβ deposition, or, cerebral amyloid angiopathy, that can be 
detected in 90% of AD patients (Vinters, 1987; Davis and Van Nostrand, 1996; Schaeffer 
et al., 2011). Third, Iowa D694N (or D23N) missense mutation has also shown to 
increase the Aβ fibril assembly by changing the β-sheets conformation of Aβ40 fibrils 
(Van Nostrand et al., 2001; Meredith et al., 2009). This mutation is also associated with 
severe cerebral amyloid angiopathy, but, unlike the Dutch mutation, the main 
representation of which was cerebral hemorrhages and dementia, the Iowa D694N is 
complimented by widespread neurofibrillary tangles, and unusually extensive 
distribution of Aβ40 in plaques in AD brains (Grabowski et al., 2001; Shaeffer et al., 
2011). Moreover, since both the Dutch and Iowa mutations lead to the loss of a negative 
charge in Aβ, the combination of those two result in more robust fibrillogenic and 
pathogenic properties in cerebrovascular smooth muscle cells and brain parenchyma 
(Van Nostrand et al., 2001). Lastly, the Thy-1 promoter was used to increase the 
expression of the mutations of “humanized” APP mRNA levels (Andra et al., 1996).  
Interestingly, despite attempts to increase the expression of APP, this mouse 
model showed decreased expression of APP compared to endogenous levels of APP in 
wild type mice, suggesting that overexpression of APP is not necessary for developing AD 
pathology.  Furthermore, it was shown that clearance of mutant Aβ into the circulation 
82 
 
was poorer in this transgenic model than in wild-type mice. Amyloid accumulation in 
cerebral blood vessels and diminished low-density lipoprotein-1 (LRP-1)-mediated 
transport across the blood-brain barrier in the cerebral microvasculature is attributed to 
this Aβ clearance deficit (Deane et al., 2004; Van Nostrand et al., 2004; 2005; 2006). 
Previous investigators have pointed out that in this AD mouse model the vascular 
deposits are fibrillar, but the deposits in the parenchyma primarily exhibit the diffuse 
type of plaque; this is in accord with the type of pathology seen in human carriers of the 
Dutch and Iowa mutations (Levy et al., 1990; Grabowski et al., 2001; Van Nostrand et al., 
2004). It has also been mentioned that in this mouse model, the classic, neuritic or core 
amyloid plaques, though seen occasionally in the parenchyma, were a very rare event 
and did not appreciably increase with the age (Van Nostrand et al., 2004). Most 
importantly, the transgenic mice that we used for the current study have shown deficits 
in spatial learning and memory tasks, implying that despite the fact that lack of classic 
AD pathology, the memory impairments are still pronounced (Van Nostrand et al., 
2007).  
We used both light and electron microscopy to examine the distribution and 
morphology of plaques in transgenic mice of different ages. To determine the extent of 
microglial involvement we used isolectin B4 (Ib4) which binds to α-D-galactosyl that is 
found on the cytoplasmic and intracytoplasmic membranes of reactive microglia (Streit 
and Kreutzberg, 1987; Streit, 1990). We then examined the ultrastructure of neurons and 
glial cells in the vicinity of the plaques identified by IB4 staining to characterize the 
extent of neuronal dystrophy. We found that activated microglia were concentrated in 
areas where microvascular fibrillar amyloid content was the highest, suggesting that 
microglial activation is strongly related to the vascular pathology (Van Nostrand et al., 
2005). We also describe the progressive increase in the distribution of activated 




Materials and Methods 
 
A total of 17 mice were used for the experiments. Thirteen mice were C57BL/6-Tg 
(Thy1-APPSwDutIowa) BWevn/J, a transgenic model of Alzheimer’s disease (TgSwDI; 
this model expresses neuronally derived human amyloid β-precursor protein, APP gene, 
770 isoform, containing the Swedish K670N/M671L, Dutch E693Q and Iowa D694N 
mutations, under the control of the mouse thymus cell antigen 1, theta, Thy1, promoter). 
Five TgSwDI mice were used for transmitted light microcopy (ages 1, 4, 6, 8 and 14 
months).  Three TgSwDI mice were used for confocal microscopy (ages 1, 4 and 13 
months).  Five TgSwDI mice were used for electron microscopy (ages 1, 4, 6, 14 and 20 
months).  Electron microscopy results were compared to tissue obtained from one 24 
month old Tg2576 mouse (containing only one Swedish mutation in APP gene). As a 
control for both light and confocal microscopy, 3 wild type C57BL/6 mice were used 
(ages 21 days, 4 and 6 months). All the methods used were approved by the University of 
Louisville Animal Care and Use Committee and conform to the National Institutes of 
Health guidelines.  
All mice were given a lethal dose of Avertin (0.3 ml/g) by intraperitoneal 
injection (for Avertin preparation, see materials and methods in chapter III). After this, 
the mice were transcardially perfused with either a solution of 4% paraformaldehyde in 
0.1M phosphate buffer pH 7.4 (PB; for transmitted light and confocal microscopy) or a 
solution of 2% paraformaldehyde-2% glutaraldehyde in PB (for electron microscopy). 
The mice were then decapitated and the fixed brains were carefully removed from the 
skulls. The brains were cut into 50 µm thick parasagittal sections using a vibratome and 
the sections were collected and placed in PB. The sections were then processed to reveal 
the presence of amyloid or the type 3 zinc transporter (ZnT3; using 
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immunohistochemistry), or activated microglial cells (using the binding of Griffonia 
simplicifolia isolectin B4; IB4), or prepared for electron microscopy as described below.  
Amyloid and ZnT3 staining for transmitted light microscopy 
Sections were incubated in a solution of 10% normal goat serum (NGS) and 0.1% 
Triton X-100 in phosphate buffered saline (0.01M PB with 0.9% NaCl; PBS) for 30 
minutes and then placed in antibody solutions overnight at 4ºC. To reveal the presence 
of amyloid, sections were incubated in 1:1000 dilution of the mouse anti-amyloid 
antibody (clone 4G8, a synthetic polypeptide binding to 17-24 residues of beta-amyloid; 
Cat. No. SIG-39220, Covance) in 1%. NGS and PBS. To reveal the presence of ZnT3, 
sections were incubated in a 1:2000 dilution of rabbit anti-ZnT3 (Cat. No. 197 002, 
Synaptic Systems Inc.) in 1% NGS and PBS. 
The next day the sections were rinsed in PB (three 10 minute washes) and then 
transferred to 1:100 dilutions of either biotinylated goat anti-mouse IgG (to reveal 
amyloid) or goat anti-rabbit IgG (to reveal ZnT3; Vector Laboratories, Burlingame, CA) 
in 1% NGS/PBS for 1 hour at room temperature. The sections were then rinsed in PB 
(three 10 minute washes) and incubated for 1 hour in a solution of avidin and 
biotinylated horseradish peroxidase (ABC solution, Vectastain, Vector Laboratories, Inc., 
Burlingame, CA). The sections were then rinsed in PB (three 10 minute washes) and 
subsequently reacted with nickel-enhanced diaminobenzidine (DAB) for 5 minutes. After 
thorough rinses in PB, the sections were mounted on slides, dehydrated in the alcohol 
series, cleared in a solution of citrosolve, and coverslipped for light microscopy 
examination. A Leica DMLB microscope equipped with a camera Exi Aqua from 
QImaging was used to capture images of the stained sections.  
IB4 staining for transmitted light microscopy 
To reveal the presence of activated microglial cells (Streit and Kreutzberg, 1987; 
Streit, 1990, Streit et al., 2007), sections were incubated overnight in a 1:1000 dilution of 
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biotinylated-IB4 (Cat. No. I21414, Invitrogen) in PBS. The next day the sections were 
rinsed in PB (three 10 minute washes) and incubated for 1 hour in ABC solution.  The 
sections were subsequently rinsed, reacted with DAB, mounted and coverslipped, and 
images captured as described above.  
Amyloid, ZnT3 and IB4 staining for confocal microscopy 
For confocal microscopy, sections were incubated overnight in primary 
antibodies and IB4 as described above. The sections were then rinsed in PB and 
incubated for 1 hour in a solution of 1% NGS and PBS containing a 1:100 dilution of a 
goat-anti-mouse antibody conjugated to Alexafluor-488 (to reveal amyloid; Cat. No. 
A11059, Invitrogen), a 1:100 dilution of a goat-anti-rabbit antibody conjugated to 
Alexafluor-546 (to reveal ZnT3; Cat. No. A11008) and a 1:100 dilution of strepavidin 
conjugated to Alexafluor-633 (to reveal IB4; Cat. No. S21375; Invitrogen). The sections 
were subsequently rinsed in PB, mounted on slides and coverslipped with Prolong® 
Gold Antifading reagent (Invitrogen). Images of the sections were then captured with an 
Olympus Fluoview confocal microscope.  
Electron microscopy 
To prepare the tissue for electron microscopy, selected sections from TgSwDI 
animals were postfixed in 2% osmium tetroxide, dehydrated in ethyl alcohol series and 
incubated in Durcupan resin overnight in a vacuum chamber. The next day, these 
sections were flat embedded in Durcupan resin between two sheets of Aclar plastic (Ladd 
Research, Williston, VT) and cured for 48 hours at 60oC. Using a light microscope, the 
embedded sections were examined to selected areas of interest. These selected areas 
were then mounted on resin blocks and ultrathin sections (70-80 nm) were cut with an 
ultramicrotome using a diamond knife. Ultrathin sections were collected on Formvar-
coated nickel slot grids. After air drying the sections were stained with a 10% solution of 
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uranyl acetate in methanol for 30 minutes.  They were then examined with a Phillips 
CM10 electron microscope and images were captured using SIA-12C camera.  
 
Results 
Amyloid and IB4 staining co-localize in TgSwDI mice  
 As illustrated in Figures 4.1 - 4.3, we found that, in tissue collected from TgSwDI 
mice, amyloid antibody staining was difficult to detect before 13 months of age. At this 
age, we found that binding of the IB4 robustly stained all areas that were stained with 
the amyloid antibody (Figures 4.1 and 4.2). In the cortex, both staining methods revealed 
areas resembling previous descriptions of amyloid plaques. DAPI staining of the same 
sections revealed a large number of glial cell nuclei distributed in the vicinity of the 
plaques (Figure 4.1), suggesting that IB4 staining reveals the presence of activated 
microglia, as previously reported (Streit and Kreutzberg, 1987; Streit, 1990).  In the 
hippocampus, amyloid and IB4 staining overlapped in the mossy fiber area, a region 
known to be one of the earliest areas affected by amyloid plaque pathology (Braak and 
Braak, 1991).   
Progression of IB4 staining with age  
 We utilized IB4 binding to examine the progression of plaque deposits in tissue 
collected from TgSwDI mice of different ages.  As a control, we stained tissue collected 
from P21 WT mice (Figure 4.3A) and did not find any signs of staining in any areas of the 
brain. In tissue collected from 4-month old TgSwDI mice, we detected a small amount of 
IB4 staining in the subiculum area, immediately ventral to the forceps major of the 
corpus callosum (Figure 4.3B). In 6 month old TgSwDI tissue, the IB4 staining expanded 
to include the CA1 and CA2 hippocampal areas along the alveus and oriens layers of the 
hippocampus, and a few labeled spots were detected in the mossy fibers area (Figure 4.3 
C). Also, in tissue from 6 month old mice, labeled aggregates of presumed activated 
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microglia were detected in the deep layers of the neocortex dorsal to the hippocampus. 
In 14-month old TgSwDI tissue, IB4 staining was detected in most of the hippocampus 
and surrounding areas, from the subiculum through CA1, CA2 and CA3 to the densely 
labeled mossy fibers (Figure 4.3D, E). Thus at 14 months of age, the IB4 staining was 
mostly distributed within areas of major hippocampal connections, such as the alveus, 
mossy and Schaeffer fibers. By 14 months, IB4 staining was also observed in the lower 
layers of the surrounding cortex, with occasional diffuse labeling in the more superficial 
layers of visual and somatosensory cortex. By 20 months of age, TgSwDI IB4 staining 
was observed in the hippocampus, many areas of the neocortex, as well as the striatum 
(Figure 4.4). Examination of IB4 staining at high magnification revealed that the 
isolectin binding was often concentrated around blood vessels in both the cortex and 
subiculum as well as in olfactory bulb (figure 4.5) 
Ultrastructure of plaques in Tg2576 mice 
 We first examined the ultrastructure of plaques in tissue obtained from a 24 
month old Tg2576 mouse. This mouse model of Alzheimer’s disease is known to produce 
plaques that display morphological characteristics similar to those observed in human 
tissue (Terry et al., 1963; Masliah et al., 1996; Dikranian et al., 2012; Hsiao et al., 1998; 
Irizarry et al., 1997; Takahashi et al., 2002). Figure 4.6 illustrates an example of a mature 
plaque from the frontal cortex of the 24-month old Tg2576 mouse. This plaque contained 
a dense core of Aβ fibrils, giving it a characteristic star-shape appearance. Individual Aβ 
fibrils extended from the core (figure 4.7) in a flame-like fashion. Processes of microglial 
cells were distributed between the Aβ fibrils (figure 4.6 and 4.7 yellow asterisks). Many 
of the Aβ fibril-filled invaginations were in the close proximity to rough endoplasmic 
reticulum (figure 4.6, 4.7). Presumed astroglial processes were also observed 
surrounding the plaque core (figure 4.6, 4.7). These processes have a lighter appearance 
and lack rough endoplasmic reticulum (Masliah et al., 1996; Dikranian et al., 2012). 
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Surrounding the amyloid core is a corona of dystrophic neurites. Thus, this type of 
plaque is referred to as a “neuritic plaque” (figure 4.8). These dystrophic neurites contain 
dense lamellar bodies and vacuoles.  
Ultrastructure of plaques in TgSwDI mice 
 We next examined the ultrastructure of plaques in tissue obtained from 13 month 
and 20 month old TgSwDI mice. In this model, neuritic plaques were primarily 
distributed in perivascular areas, with accumulations of Aβ observed in the endothelial 
cells making up vessel walls, and microglia and dystrophic neurites surrounding the 
vessels (Figure 4.9).  
The classification of microglial cells and their processes as well as other types of 
cells seen in the plaque periphery was based on careful comparison with the microscopic 
characteristics of similar cells described in previous investigations (Stalder et al., 1999; 
Wegiel et al., 2004; Van Nostrand et al., 2005; Dikranian et al. 2012). As described in 
previous studies of neuritic plaques, microglial cells are distributed in the immediate 
proximity of the amyloid core. The cytoplasm and nuclei of microglial cells are darker 
than that of neurons. Microglial cells contain abundant rough endoplasmic reticulum 
and occasional mitochondria (Figures 4.10, 4.11). Occasionally, some cells with very dark 
nuclei and very dense cytoplasm were found near the site of amyloid pathology (figure 
4.12). These cells are presumed to be dystrophic or degenerating microglia cells based on 
the appearance of the nucleus and cytoplasm filled with vacuoles and other inclusion 
bodies.  
The mossy fiber region of the hippocampus, which, as described above, stains 
densely with IB4, rarely exhibited typical neuritic plaques. Instead, abundant microglial 
processes filled with Aβ fibrils were observed to extend between the neurites with little 
extracellular amyloid (figure 4.13). In the frontal cortex, we occasionally observed core-
like Aβ accumulations inside microglia or neurons that were not associated with blood 
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vessels (figure 4.14). Dystrophic neurites and neurons with amorphous inclusions 
resembling lipofuscin granules and vacuoles were also observed in areas in which there 
were no discernible amyloid deposits (Figure 4.15).  
The dystrophic neurites were predominantly filled with dense accumulations of 
intracellular debris such as cytoplasmic membrane and myelin, autophagic vacuoles and 
degenerating mitochondria (Terry et al., 1963, Masliah et al., 1996; Dikranian et al., 
2012). Mitochondrial changes in the neuritic processes ranged from mitochondrial 
clumping and gradual degeneration to complete absence of distinct organelle features 
(figure 4.16). The neurites in the latest stages of degeneration were the most electron 
dense, due to increases in dense lamellar bodies and decrease in surrounding cytoplasm. 
The majority of dystrophic neurites were unmyelinated, although some myelinated 
dystrophic axons were present (figure 4.17). In some cases neurites were only partially 
myelinated (Figure 4.17). In hippocampus, the degenerating neurites exhibited electron-
dense nuclei and axoplasma (figure 4.16E). Degenerating axon terminals were also 
observed. These terminals contained electron dense accumulations of synaptic vesicles 
(figure 4.18).   
Finally, some core-like plaque structures were identified inside neuronal 
processes with adjacent bundles of fibrils resembling neurofibrillary tangles (figure 4.19) 
(Huang et al., 2001; Ramsden et al., 2005). The origin of these fibrils is unclear, as they 
could be fibrils of Aβ or condensed neurofilaments.  Similar fibril bundles were observed 




The progression of microglial involvement and the ultrastructure of pathological 
changes in a triple transgenic mouse model of AD were investigated in this study. First, 
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we have shown that Ib4 labeling of activated microglia is a useful tool for investigating 
the pathological progression of AD. The co-localization of staining for Aβ and activated 
microglia suggests that Aβ formation and deposition directly or indirectly activate 
dormant microglia and attract them to sites of fibrillar amyloid accumulation (Stalder et 
al., 1999; Wegiel et al., 2004; Nagele et al., 2004). However, there are many questions 
that remain unanswered. The most important question is why these pathological changes 
have such a specific site of onset in the brain. Regardless of species or the type of 
mutation initiating plaque formation, pathological changes are initiated in similar areas 
and progress in a defined sequence with aging (Braak and Braak, 1991; Van Nostrand et 
al., 2004; Thal et al., 2001, 2006).  
In the TgSwDI model we used, the progression of plaque formation in the brain 
followed the general course described for human AD plaque progression.  We observed 
sequential plaque formation that started in the subicular area and spread to involve the 
majority of the hippocampus and the cortex as the animals aged. Why the 
subiculum/CA1 and enthorhinal cortex are particularly prone to the development of 
pathology is still unclear. In the TgSwDI used in this study the activated microglia were 
mostly located in the alveus layer of the hippocampus following activation in the 
subiculum. The alveus layer contains a large number of myelinated axons coming from 
pyramidal cells of the subiculim and other parts of hippocampus to the fimbria/fornix, 
the major output tract for hippocampus (Knowles, 1992). In addition, dense 
distributions of Aβ and microglia predominated in the mossy and Schaeffer fibers, major 
incoming excitatory pathways. This suggests that, as animals age, the development of 
pathology is related to areas in which there are abundant excitatory synaptic 
connections. The various mechanisms of excitotoxicity (reviewed in detail by Kumar et 
al., 2013), are considered to be possible triggers of AD pathology (Chen et al., 1992; Chen 
and Lipton, 1997). Moreover, one of the two medications available as a treatment option 
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for AD patients is memantine, a N-methyl-d-aspartate receptor (NMDAR) antagonist 
which is thought to effectively block the neurotoxicity of glutamate, slowing neuronal 
loss and cognitive deterioration (Chen and Lipton, 2006; Hellweg et al., 2012; Cavalli et 
al., 2013). Another hypothesis regarding the initiation and progression of Aβ 
accumulation within certain hippocampal areas is related to the abundant zinc storage in 
the areas where plaques develop first. Diverse mechanisms have been proposed that 
could explain why changes in zinc levels may lead to the plaque formation (Paoletti et al., 
2009). Future experiments will be necessary to investigate those possibilities.  
Plaque ultrastructure  
Although many histopathological characteristics of the plaques observed in this 
study were very similar to the well known changes in humans and other mouse models of 
AD, there were several unique morphological differences in the TgSwDI mice. Despite 
thorough investigation, we were unable to find dense cores of extracellular amyloid in 
the subiculum, mossy fiber area or cortical parenchyma resembling the ones that we 
observed in the Tg2576 mice, even though the microglial cells and Aβ staining were 
obvious in those areas in the TgSwDI mice. The propensity of altered Aβ fibrils produced 
after Dutch and Iowa mutations to accumulate near or in the walls of brain vasculature 
has been previously described (Van Nostrand et al., 2004, 2005). Our careful 
ultrastructural examination of areas densely stained with Ib4 suggests that in TgSwDI 
mice the perivascular depositions of Aβ may be analogous to the dense cores of neuritic 
plaques. Indeed, most of the pathological elements of AD were seen in the vicinity of the 
vessels (figures 4.9, 4.10, 4.11), including processes of activated microglia and dystrophic 
neurons.  
The reason why there is such a strong affinity for Aβ fibrils to accumulate around 
the cerebral vasculature may lie in the type of Aβ fibrils produced, and the 
conformational alterations that are produced by the mutations (Van Nostrand et al., 
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2001, 2006; Herzig et al., 2004; Baumketner et al., 2008; Meredith et al., 2009; Chen et 
al., 2011). The increased ratio of Aβ40/Aβ42 in the plaques of Dutch and Iowa mutants 
leads to the predominant accumulation of Aβ40 in the vasculature. Despite the solubility 
of Aβ40, the several fold increase in its concentration in TgSwDI causes its retention in 
the brain (Van Nostrand et al., 2004). Lin et al., (2013) suggested that the Aβ40/Aβ42 
ratio determines the type of plaque formed, with increased Aβ40 primarily responsible 
for diffuse plaque formation. Shifting the Aβ40/Aβ42 ratio toward more Aβ42 
formation, by introducing additional mutations (for example, mutated presenelin-1), 
redistributes amyloid pathology from vascular to more parenchymal (Levy et al., 2006; 
Herzig et al., 2004; Chen et al., 2011). Interestingly, despite the pronounced perivascular 
pathological changes we observed in the TgSwDI mice, the vascular lumen were not 
occluded and the overall vascular shape was preserved in the most affected vessels 
(figure 4.9, 4.11). This suggests mechanisms of amyloid retention other than simple 
mechanical occlusion by Aβ (Van Nostrand et al., 2004; Deane et al., 2004).  
The abundant presence of the diffuse type of plaque (i.e. plaque that are devoid of 
both a dense core and surrounding neurites and inflammatory types of cells), was 
previously shown in this model (Van Nostrand et al., 2004, 2005) and is in accordance 
with the types of plaques seen in carriers of the Dutch and Iowa mutation (Levy et al., 
1990; Yamaguchi et al., 2000; Grabowski et al., 2001; Van Nostrand et al., 2004). 
However, this type of plaque characteristic has mainly been described based on the 
cloud-like appearance of Aβ staining observed with the light microscope, and it is 
extremely difficult to discern subtle collections of Aβ fibrils at the electron microscopic 
level without special immunogold staining (Yamaguchi et al., 2000).  
The presence of diffuse Aβ fibrils exclusively would not explain the symptoms of 
AD, which are more related to neuronal degeneration and loss. The abundant staining of 
activated microglia co-localized with Aβ staining that we observed in this study implies 
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an interaction between amyloid deposition and immunological reactions. Occasionally, 
we found Aβ accumulations inside the microglial processes in the areas remote from 
microvasculature, suggesting attempts to phagocytose and isolate the Aβ (figures 4.14, 
4.15).   
The ultrastructure of degenerating neurites was similar to that observed in 
human brains and other models of AD (Terry et al., 1963; Masliah et al., 1996; Perl, 
2010; Dikraian et al., 2012). Axons gradually lost their internal structure, showing 
clumps of mitochondria or complete autophagocitosis and loss of myelin sheaths. Some 
synapses could be still visualized despite the gross pathology of presynaptic axons, but 
these preserved synapses were rarely found in the areas of the intense pathology. This 
synaptic wasting is considered to be one of the strongest correlates of cognitive 
deterioration (Terry et al., 1991; DeKosky et al., 1996; Scheff and Price, 2003; 
Venkitaramani et al., 2007; Reddy and Beal, 2008; Bayer and Wirths, 2010). The loss of 
mitochondrial function is also implicated in synaptic pathology through increased 
oxidative stress and other mechanisms (Reddy et a., 2010; Quiroz-Baez et al., 2013). The 
compaction of this organelle and loss of normal cytoskeletal characteristics by the axons 
as well as Wallerian degeneration imply an impairment of axonal transport (Wirths et 
al., 2006; Buki and Povlishock, 2006; Dikranian et al., 2012) that likely contribute to the 
overall neuronal dysfunction.   
The role of microglia in the pathology of AD is a topic of intense debate. In 
TgSwDI mice, microglia appear to be present at all sites where Aβ staining is found. It is 
not understood what causes the microglial activation in AD. It has been proposed that Aβ 
itself induces a chemotaxis of microglia (Huang et al., 2010). Microglia have been found 
to internalize Aβ fibrils through special receptors (Paresce et al., 1996; Liu et al., 2005, 
2012). Meyer-Luehmann et al (2008) showed that plaques can form within 24 hours, 
with activated microglia are attracted to the plaque within 1-2 days, followed by 
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progressive neuritic changes over the next several days or weeks.  The size of the plaque 
surrounded by microglia remains constant over time which presumes a failure of 
microglia to efficiently phagocytose amyloid. However, the reason for this presumed 
failure is not well understood (Meyer-Luehmann et al., 2008; Neumann et al., 2013). 
Cultured microglia in vitro did not show significant Aβ degradation abilities. The cells 
also showed some slow release of intact fibrils after initial uptake (Chung et al., 1999). 
This could potentially mean that degradation of Aβ by microglial cells is naturally 
ineffective and initial unsuccessful attempts in clearing Aβ fibrils is followed by their 
release and further build up in the extracellular space. 
In our study, we found many microglial cells at the sites of Aβ deposition clearly 
showed amyloid masses inside their processes, but with no clear signs of phagocytotic 
activity, such as vacuoles, lysosomes or any inclusion bodies. In contrast, microglial cells 
that were close to dystrophic neurites showed signs of phagocytosis (figure 4.21), in 
accordance to previous studies (Terry et al., 1964; Wegiel and Wisniewski, 1990; Stalder 
et al., 1999). The participation of microglia in phagocytosis of axonal and myelin debris 
of dystrophic neurites (Tanaka et al., 2009; Hosmane et al., 2012) is very important. 
Many examples of axonal Wallerian type of degeneration and loss of myelination in 
TgSwDI and other models imply a great amount of degrading myelin is cleared by the 
microglia. Myelin proteins impede axonal regeneration and repair and have also been 
shown to inhibit phagocytosis by microglia (Wang et al., 2002; Gitik et al., 2011; 
Neumann et al., 2013). To further complicate matters, it has been found that myelin 
clearance is very inefficient after Wallerian type of degeneration in the central nervous 
system (Gaudet et al., 2011; Neumann et al., 2013). Thus, the promotion of microglial 
activity could be beneficial for improved neural functioning in AD. On the other hand, 
persistent microglial activation could potentially cause chronic inflammation and 
neurodegeneration through various cytokines and reactive oxygen species (McGeer and 
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McGeer, 1995; Rogers et al., 1996; Stalder et al., 2001). Also, investigations of the 
ineffective involvement of astrocytes in the clearing of Aβ and cellular debris (Nagele et 
al., 2004) are interesting in light of the fact that we found evidence of the presence of 
astrocytic processes in and around plaques in the TgSwDI mice.  
In summary, our investigation of TgSwDI mice confirms most of previously 
described histopathological features of this unique AD model. It was estimated that 
direct contact with capillaries was found in 91% of amyloid plaques in human (Kawai et 
al., 1990; Nagele et al., 2004). Recent studies suggested that dementia shows a better 
correlation with microvascular Aβ accumulation than parenchymal Aβ accumulation 
(Thal et al., 2003; Atterns and Jellinger, 2004). Failure of anti-amyloid therapy to 
improve cognitive functioning in human trials (Sperling et al., 2012) shifted the previous 
“amyloid cascade” hypothesis toward searches for other causes of AD etiopathogenesis. 
In this case, TgSwDI mice represent a suitable model for investigation of the 






Figure 4.1 Confocal image of Aβ plaques and associated microglia in 13-month old 
TgSwDI. (A) 4G8-staining of cortical plaques for Aβ co-localizes with (B) Ib4 staining 
for activated microglia. (C) Higher magnification image of the cortical plaque stained 
for 4G8 co-localizes with (D) Ib4 staining of the same plaque. (E) Superimposed image 
of (C) and (D), ZnT3-staining co-localize; DAPI-staining reveals dense nuclei of 
microglia (black arrow) and more lucid nuclei of neurons (white arrow) lying in the 
vicinity of the plaque. Scale bar in (A) = 10 µm and applies to (B). Scale bar in (C) = 5 








































Figure 4.2 Confocal image of mossy fibers (MF) stained for Aβ (A, C,E) with 4G8 and 
microglia with Ib4 (B,D,F). There is no signal for 4G8 or Ib4 in P21 WT (A, B) and 4-
month old TgSwDI mice (C, D) noted, but strong signal for both appears in 13-month 
old TgSwDI and overlap (E, F). Scale bar (A) and (B) = 10 µm; scale bar (C) and (D) = 




















Figure 4.3 Progression of AD pathology in TgSwDI at different ages. (A) P21 WT mouse 
hippocampus stained for Ib4, no specific areas of labeling is noted. (B) Ib4 staining for 
activated microglia in 4-month old TgSwDI. The sharply defined clusters of labeled 
microglia noted (arrow) in subiculum. (C) 6-month old age TgSwDI shows activated 
microglia spreading to the alveus layer of CA1. (D) and (E) At 14 months of age, 
TgSwDI shows activated microglia in every area of hippocampus and also in the layer 
of the cortex just above hippocampus (arrows). (E) Hippocamus of 8-month old 
TgSwDI stained for 4G8 against Aβ shows that stained areas (dotted areas pointed by 
arrows) are the same areas that contain labeled activated microglia. Scale bar (A) = 



















Figure 4.4 Sequential saggital sections of 20-month old TgSwDI stained for Ib4. The 
plaques are noted in the cortex, including frontal part (E and F), in and around 
hippocampus (A through F) and striatum (D-F). The inset demonstrates 20-month old 
TgSwDI hippocampus after Ib4 staining with the major anatomical areas labeled. MF 





































Figure 4.5 Ib4 staining in 20-month old TgSwDI. Activated microglia is concentrated 
around the vessels (asterisks) in (A) subiculum; (B) frontal cortex; (C) alveus; (D) 


















Figure 4.6 Mature plaque core in 24-month old Tg2576. Red asterisk – amyloid 
core; yellow asterisks – surrounding core microglial processes, black arrows – 
astrocytic processes; white arrow example of amyloid invagination into surrounding 
microglia; yellow arrow - RER. Inset shows plaque at light microscopic level with red 



















Figure 4.7 Mature plaque core with Aβ fibrils, Tg2576 24-month old. Higher 
magnification of Aβ fibrils (black arrow) arranged toward the core in microglial 
process (yellow asterisk). Red – amyloid dense core, black asterisk – astroglial 















Figure 4.8 Amyloid core periphery Tg2576 24-months old, lower magnification. Red 
asterisk – amyloid core; white asterisks – microglial processes; yellow asterisks – 
dystrophic neurites in the different stage of degeneration. The dystrophic neurites form 















Figure 4.9 TgSwDI 20-month old perivascular plaque. Red asterisk – Aβ accumulation 
surrounded by microglial process (yellow asterisk); black arrow – basement 
membrane; M – microglial nucleus; L – capillary lumen; N – normally appearing 













Figure 4.10 TgSwDI 13 month old perivascular plaque. Note Aβ fibrils (red asterisk) 
form an immediate contact with dystrophic neuron (dn) and surrounded by microglial 
processes (yellow asterisks). L – capillary lumen; M – microglial nucleus; white arrow 
– RER with ribosomes; black arrow – basement membrane; yellow arrows – 















Figure 4.11 TgSwDI 20-month old frontal cortex perivascular plaques. Three microglial 
cells with multiple amyloid depositions inside surround two affected capillaries. Red 
asterisks – Aβ accumulations surrounded by microglial processes (yellow asterisks); 
M- microglial niclei; as – astrocytic processes; L – capillary lumen; dn – unmyelinated 














Figure 4.12 Dying microglial cell in TgSwDI 13-month old, cortex.  Dark nucleus (M) 
and cytoplasm (yellow asterisks). Cytoplasm shows signs of phagocytosis: vacuoles 
(black arrow) and inclusion bodies (white arrow) inside. Dystrophic neuron (dn) and 















Figure 4.13 Microglial process (M) in mossy fibers of TgAD 13-month old mouse. The 
process filled with fibrillar material, surrounded by dystrophic neurites (dn). Process 














Figure 4.14 Microglial cells (M) in brain parenchyma of frontal cortex in 20–months old 
TgSwDI filled with (A) multiple or (B) single Aβ depositions (red asterisks) in their 























Figure 4.15 Neuron (N) surrounded by microglia (M) in 20-month old TgSwDI frontal 
cortex. Note the lipofuscin accumulations (white arrows) and vacuoles (black arrow) 
inside the neuron. Red asterisk shows Aβ accumulation inside microglial process; dn – 













 Figure 4.16 Different stages of neurite degeneration, TgSwDI 13-month old. (A) 
preserved neurofilaments, RER (yellow arrow) and clumping of mitochondria (black 
arrows); udn – unmyelinated dystrophic neurite; mdn – myelinated dystrophic 
neurite. (B) Occasional mitochondria are seen (black arrows), areas with 
neurofilaments are still present; some inclusion bodies (white arrow), dense bodies 
(green arrow) and vacuoles (yellow arrows) are noticed. (C) No mitochondria are 
noticed, very little areas with neurofilaments; majority of area filled with dense bodies, 
inclusion bodies and vacuoles.  (D) Late stage of myelinated axon degeneration, filled 
with dense bodies and vacuoles, no spaces with neurofilaments could be seen. (E) 
Neuronal body in the initial stage of apoptosis with pyknotic nucleus and dense 
cytoplasm without any visible organelles. Scale bar (A) 2 µm and applies to (B, C and 









































Figure 4.17 Loss of myelination by degenerating axon of TgSwDI 13-month old  (A) 
cortex (B) hippocampus. Black arrows show myelinaed part and white arrows show 
umyelinated part of the axons; dn – dystrophic neuron. Scale bar = 2 µm and applies to 







               









Figure 4.18 Degenerating synaptic terminal in 13-monh old TgSwDI. Terminal (T) of 
degenerating axon (dn) forms multiple synapses (black arrows) with dendritic spines 
and has visible dense bodies (yellow arrow) among the normal appearing terminal 














Figure 4.19 Intracellular amyloid core (red asterisk) inside the axon of 20-month old 
TgSwDI. Adjacent fibrillar bundles (black arrow) are possibly of amyloid origin; note 

















Figure 4.20 Fibrillar bundles in molecular layer of dentate gyrus in 13-month old 

















Figure 4.21 Microglial cell near dystrophic neurons showing signs of 
phagocytosis in 20-month old TgSwDI. Microglial cell (M) at periphery with lipofuscin 
(white arrow), vacuoles (yellow asterisk), inclusion bodies (black arrow) and vesicles 














SUMMARY, THEORETICAL CONSIDERATIONS AND FUTURE 
DIRECTIONS 
               In this dissertation, which consists of several distinct chapters, the possible 
mechanisms of Alzheimer’s disease (AD) development and histopathological 
characteristics of disease progression are investigated using a transgenic mouse model of 
AD. This model, with introduced triple Swedish/Dutch/Iowa mutations (TgSwDI), has a 
unique histopathological presentation manifesting in more pronounced cerebral amyloid 
angiopathy, which many consider to correlate with cognitive deterioration. Synaptic 
malfunction and loss, as the consequence of still not well understood etiologic factors of 
AD, are also correlated with cognitive decline. The understanding of normal synaptic 
morphology and organization is therefore an important aspect of the continued search 
for the factors that affect synaptic malfunction and loss in AD.  
In chapter II, we compared the synaptic organization of geniculocortical and 
pulvinocortical terminals in the tree shrew.  We found several significant differences in 
the morphology of these terminals and their synaptic targets. Our results clearly 
demonstrate that the organization of thalamocortical synapses is quite different in the 
koniocortex and eulaminate cortex, although future studies will be necessary to 
determine the functional distinction between these projections. Future studies of other 
type of synapses in the koniocortex and eulaminate cortex may reveal features that 
would help to explain the different propensities of cortical regions to be affected by AD. 
In particular, AD pathology appears to primarily affect corticocortical cells. Therefore, 
future comparison of corticocortical connections may be a fruitful avenue to determine 
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differences in cortical organization that may underlie the progression of AD pathology.  
             Chapter III investigated the potential interaction between zinc and spines as a 
possible pathophysiological mechanism of AD progression. Zinc, and the type 3 zinc 
transporter (ZnT3), are thought to participate in different aspects of AD pathology. The 
earliest basis of memory deterioration is tied to the loss of dendritic spines, the most 
mature of which contain a unique organelle, the spine apparatus, which can be identified 
identified by the actin-binding protein synaptopodin. We measured changes in the levels 
of ZnT3 and synaptopodin in the cortex and hippocampus of the TgSwDI and WT mice 
at 1, 4 and 6 months of age before and after zinc precipitation via intraperitoneal 
injections of sodium selenite. Sodium selenite treatment produced no significant effect 
on the level of synaptopodin. However, we did find that ZnT3 levels were higher in 
TgSwDI at 4 months of age in both cortex and hippocampus when compared to wild type 
mice (WT) and TgSwDI mice of other ages. Also, when compared by ages, synaptopodin 
levels were higher in 4-month old WT and TgSwDI animals in both the cortex and 
hippocampus. These results suggest that zinc may be an important participant in the 
pathology of AD, but that age-related changes in ZnT3 levels should be considered when 
evaluating treatments involving the manipulation of zinc levels.  
             Despite the seemingly strong hypothesis, we were unable to uncover any 
influence of zinc levels on the formation or maintenance of mature spines. It is worth 
noting, however, that the experiments were limited by a number of factors. 1) Few 
animals available so our experimental groups were small, 2) The sodium selenite 
injections proved to be quite toxic so were unable to test more long term effects of zinc 
precipitation, 3) we used animals at 1, 4 and 6 months of age but most of the pathological 
changes in the TgSwDI model used occur after 6 months of age and 4)  the TgSwDI 
model we used does not produce the neuritic plaques typical of other AD models or the 
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neuritic plaques and neurofibrillary tangles seen in human AD brains. Thus our results 
do not rule out a relationship between zinc and spines in AD pathology.  
             We conducted a power analysis to evaluate the possibility of our experiments 
reaching statistical significance if we increased the experimental groups described in 
Chapter III. To determine the probable sample sizes required to obtain significant 
differences, power analyses were performed on mean differences that were increased by 
10% and with averaged standard deviations. Based on these power analyses, a significant 
difference would be expected in synaptopodin levels between the groups in the cortex at 
1hr in 4 month old mice using a sample size of 6-7 per group with the power to predict 
this difference of 82.9-89.3%, respectively. In the hippocampus a significant difference 
in synaptopodin may be achieved with sample sizes of 8-9 in 4 month olds at 1hr. The 
power associated with these outcomes equaled 72.9 and 78.5%, respectively. At 3hrs the 
sample required increases to 15 per group and yields a power of 74.4% to detect a 
significant difference between the groups. Differences between the groups in ZnT3 in the 
cortex could be observed using sample sizes of 6 per group at 3hrs in 4 month olds with a 
power of 93.0%. The power to detect a significant difference in ZnT3 in the hippocampus 
equaled 86.0% in 1 month olds at 1hr with 7 per group and with 5-6 per group in 4 
month olds at 3hrs with a power of 97.0 and 99.1%, respectively. Thus, further data 
collection would be necessary before drawing any final conclusions. Also, the 
experimental model could be changed by trying different zinc deprivation methods and 
different durations of zinc deprivation. The effect of increased zinc, for example via 
sensory deprivation, could also be used to assess the relationship between zinc and spine 
morphology. 
Chapter IV described the histopathological features of the TgSwDI model used in 
our studies. We showed that isolectin b4 (Ib4) staining can be successfully used to study 
the age-related progression of AD pathology. Compared to humans and other mouse 
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models of AD, we found few classic neuritic plaques (with a dense Aβ core in the brain 
parenchyma). In the TgSwDI mice used in our studies, we instead found an abundant 
number of perivascular Aβ depositions, which were surrounded by a corona of 
dystrophic neurites, microglial and astrocytic cells. Despite difference in the types of 
plaques found in different model, the timeline and sequential involvement of brain areas 
from enthorhinal/subiculum to the neocortex is similar. Overall, our results suggest that 
the TgSwDI mouse model is very suitable for the investigation of the cerebral amyloid 
angiopathy-related aspects of AD. 
           The recent human trials of anti-Aβ immunotherapy in advanced stages of AD 
pathology failed to produce significant cognitive improvement, although Aβ was 
efficiently cleared from the brain. This raised new questions and led to the revised 
thoughts concerning the etipathogenetics of AD. Preventive measures and early 
intervention, before detrimental synaptic loss occurs, is the current priority of 
Alzheimer’s research. The prevailing for almost two decades amyloid cascade hypothesis 
revealed large amount of weaknesses in its explanation of AD processes. Zinc 
dyshomeostasis was looked at as the igniting event that would precede amyloid cascade 
and could possibly explain the mechanism of amyloid formation as well as interference 
with other ultrastructural processes important for memory formation. The received data 
did not exclude importance of Aβ in the pathology of AD but it stressed the multifactorial 
nature of this disease. The existence of different oligomers of Aβ and plaque forms 
described in Chapter IV also pointed out that there are disease types with pathology 
different from the one seen in typical AD postmortem brain, but yet exhibiting the 
similar cognitive dysfunction. These findings suggest that there are more pathogenetic 
pathways are involved in AD than just amyloid cascade.   The function of microglia in AD 
is debated intensely with some authors ascribing these cells a major role in the 
aggravation of pathology while others demonstrating that AD pathology can develop 
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without microglial participation. In either case, further studies are needed to understand 
every aspect of this disease. If we understand why pathology starts in certain areas of the 
brain, this could lead to methods to prevent the initial onset of AD.  Finding ways to 
direct the balance between the necessary phagocytic properties of microglia and the 
detrimental properties of excessive microglial influx is another priority. Finally, 
investigating what role cerebral amyloid angiopathy plays in the progression of AD is 
another promising direction in AD research.  
           Despite the enormous number of patients affected by AD pathology and the 
multitude of hypotheses regarding the causes and treatment of this detrimental disease, 
we are still far from the desperately needed answers. The hope for a cure still exists while 
the minds of passionate investigators remain eager to solve one of the most complicated 
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